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Thesis Summary 
 
Pre-workout supplements (PWS), like most nutritional supplements, are classified by 
the Therapeutic Goods Administration (TGA) in Australia as complementary medicines 
and are therefore subject to much less stringent regulation compared to pharmaceuticals. 
Complementary medicines (also known as 'traditional' or 'alternative' medicines) 
include vitamin, mineral, herbal, aromatherapy and homoeopathic products. 
 
PWS comprise a group of sports supplements purported to provide consumers with a 
boost in athletic performance facilitated by the inclusion of stimulatory compounds 
usually of plant origin. Typically, PWS are multi-component in nature generally 
containing caffeine, an amine-based central nervous system (CNS) stimulant, taurine, β-
Alanine and creatine (Eudy et al., 2013). The stimulants cause cardiovascular stress 
when combined with exercise (Haller et. al, 2002). The increase in PWS-related adverse 
effect reports correlates with the increased use/prevalence in the community. 
 
The overall goal of this thesis was to determine the amounts of stimulants in PWS, both 
the biogenic amines derived from Citrus aurantium (CA) extracts as well as caffeine 
and its dimethylxanthine (DMX) derivatives. Research questions have been put forward 
relating to the components within PWS and whether they comply with any guidelines or 
regulatory limits and whether differences are evident between PWS made in Australia 
compared to overseas. To address these questions, the aims were to develop two HPLC 
protocols for the quantitation of 1) adrenergic amines present in CA-containing PWS 
and 2) caffeine and DMXs in PWS. These were the first protocols to implement a single 
quadrupole mass detector (QDa) for rapid mass confirmation in-line with UV-Vis 
detection on a reverse phase-high performance chromatography (RP-HPLC) system for 
detection of these compounds.  
 
 
 
 
II 
 
It was hypothesised that the caffeine content in overseas-manufactured PWS would be 
higher than locally-produced PWS. This was found not to be the case and, in fact, 
variations in caffeine content were minimal across the sample set. Significant 
discrepancies were found, however, between determined levels of caffeine in some 
products and that stated on their label.  
 
A highlight of this study was the development of a RP-HPLC protocol able to resolve 
the isobaric isomers, theophylline (TP) and paraxanthine (PX), not normally 
demonstrated in other similar reported methods. PX, though not a constituent of CA, 
was found in one of the overseas PWS.  Conclusive answers to the research questions 
were limited by the small sample size of CA-containing PWS in this study. For 
example, no significant differences in synephrine levels between locally and 
internationally manufactured PWS were observed in this pilot study.  Furthermore, 
when the active compounds were labelled as a ‘proprietary blend’ this posed a challenge 
to accurately compare the quantities of the key ingredients.  Future research into the 
quantification of these amines and other synthetic stimulants on a hydrophilic 
interaction liquid ion chromatography (HILIC) could result in greater sensitivity of the 
methods especially when coupled to a mass detector. 
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3 
1.1 Pre-workout Supplements – Background, Use and Regulation 
 
Pre-workout supplements (PWS) are multi-ingredient sports supplements used not only by 
individuals to improve performance, but have been playing a more prominent role in the 
general population to improve alertness (Hoffman et al., 2009). Ephedra sinica (ES) extracts 
contain sympathomimetic, ephedrine and was one of the most popular CNS stimulant before 
it was banned in 2004- after it was correlated with adverse cardiovascular effects (Gurley, 
Steelman, & Thomas, 2015). Acacia rigidula (AR) was another popular stimulant that was 
banned in 2014, due to its active ingredient’s structural similarities to methamphetamine 
(Pawar et al., 2014). Citrus aurantium (CA) is also used in dietary weight-loss supplements 
due to the purported thermogenic activity of its key component, synephrine (Bell et al., 2004). 
For example a U.S. population study found that CA-containing supplements have been 
gaining popularity as a method of boosting energy and improving health alongside multi-
vitamins in the adolescent and young adult population (Bailey, 2014). Disturbingly however, 
increased numbers of reports of adverse effects to the U.S. Food and Drug Administration 
(FDA) have raised concerns about the use and abuse of PWS consumption. The most notable 
case report was reported by Eliason et al. (2012) where two U.S. military soldiers died from 
cardiac arrest after taking a PWS containing 1,3-dimethylamine (DMAA). Unlike 
pharmaceuticals, these products do not require manufacturers to provide unequivocal 
evidence for the efficacy of their product and are often perceived to be safe for consumption 
(Hung et al., 2011). 
PWS usually contain a blend of amino acids and stimulants from plant extracts represented 
with the key composition set out in Table 1. Appendices 1-8 provide examples of PWS labels 
selected for analysis in this study. Difficulties in obtaining an accurate picture of  PWS 
ingredients stems from relaxed legal requirements for labelling of ingredients for 
complimentary medicines as well as in the inclusion of components as ‘proprietary blends’. 
For example, the ingredient Panax notoginseng, labelled in Gold standard Preworkout 
(Optimum Nutrition), was identified as American ginseng extract in Muscle Prime (Allmax 
Nutrition). While Table 1 includes ingredients from only 8 selected PWS there are literally 
hundreds of PWS formulations available, some made in Australia and others from overseas 
sources where manufacturing standards may be less stringent. Many PWS contain 
phytochemicals with distinctive CNS or cardiovascular stimulant properties. Although some 
4 
of the plant extracts from which these derive may have been tested individually, the safety 
and/or efficacy of the combination of plant extracts has not been established.   
β-Alanine was found to be a common ingredient in many PWS. β-Alanine is a nonessential 
amino acid produced in the liver and obtained from protein rich foods in the diet. The basis 
for its use in PWS is that it is a substrate, along with histidine, for carnitine formation in 
muscle cells (Caruso et al., 2012). Carnitine’s main role is to facilitate the transport of 
medium to long chain fatty acids into the mitochondria however, due to the basicity of the 
imidazole ring; it also provides intramuscular buffering thereby preventing acidosis during 
prolonged muscle contractions. Another common ingredient found in PWS is creatine, 
another amino acid-derived compound produced by the kidneys and liver to serve as a high 
energy phosphate reservoir for skeletal muscle cells. 
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Table 1 ingredient formulation of Ephedra-free dietary supplements  
Ingredients  
360 
RageTM
 
Beast 
ModeTM DyNOTM 
Ergo 
BlastTM 
Gold 
standard 
PWTM 
Kardio 
FireTM 
Muscle 
PrimeTM 
Pump 
HDTM 
BCAA 
 
  
 
   
  
B alanine 
  
  
  
 
 
L-tyrosine 
 
 
 
 
 
  
  
Arginine 
 
 
    
 
  
Citrulline Malate      
 
 
 
  
Alpha Lipoic Acid 
      
 
  
N-Acetyl-Cysteine 
 
  
  
 
 
 
  
Creatine  
   
  
 
  
Taurine 
      
 
  
Caffeine anhydrous   
 
      
Grape Seed extract   
      
  
Maritime Pine Tree 
Bark extract 
 
      
  
Toothed Clubmoss 
extract 
 
  
 
   
  
Higenamine HCl 
  
  
   
  
Raspberry ketone 
     
 
 
  
Olumbago zeylanica 
extract 
       
 
Echinacea purpurea 
extract 
       
 
Rhodiola root extract 
  
 
    
 
Astragalus 
membranaceus extract 
    
 
  
  
Panax notoginseng 
extract 
    
 
 
 
  
CA extract 
 
 
      
Co-enzyme Q 10 
   
 
  
 
  
Cordyceps 
      
  
Hawthorne Berry 
extract 
      
 
  
Ginko Biloba Extract 
 
 
 
 
  
  
Selenium 
      
 
  
Niacin (Vit. B3) 
 
  
 
 
 
  
Vitamin B6 
 
  
 
 
 
  
Vitamin B12 
 
  
 
 
 
  
Vitamin C 
   
  
  
  
Maltodextrin 
  
  
 
 
 
  
Natural and Artificial 
flavourings  
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Earlier this decade, reports of PWS consumption by individuals outside the athletic 
performance arena surfaced. For example, workers engaged in occupations involving long (or 
late-night) shifts were taking advantage of the stimulatory effects of PWS to prolong alertness 
(Simmons, 2013). Management of the Bowen Basin mine in Western Australia banned the 
use of PWS, “JACK3D”, because of the perceived risks involved in concurrently operating 
heavy machinery and/or reduced decision-making ability (Duffy, 2012).  
For a large segment of the general population, the desire to lose weight via consumption of 
weight-loss or ‘fat-burning’ supplements have expanded the sale of CA-containing 
supplements into this very lucrative market. Many of the individuals in this segment of the 
community may be overweight or obese; currently taking prescription medication; or are of an 
older age and already predisposed to cardiovascular diseases. These factors heightened the 
risk and thus a need for reliable and unbiased research into the safety and efficacy of the 
individual compounds in PWS was warranted. There needs to be a greater focus on the 
potential interactions between PWS additives and/or medications.  
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1.1.1 Common Herbal Extracts Found in PWS 
 
1.1.1.1 Ephedra Sinica (ES)  
 
Ephedra sinica has been used in traditional Chinese medicine for many centuries and is the 
botanical source of ephedrine alkaloids, pseudoephedrine, norpseudoephedrine and 
norephedrine. These CNS-active compounds resemble epinephrine (as well as amphetamine) 
in structure and this is likely responsible for their similarity in pharmacological effects.  
Ephedra was an ingredient in PWS for around 10 years (1994-2004) and during this time 
experienced considerable controversy. A full historical review of ephedra use in the USA has 
been documented (Palamar, 2011). Despite the purported claims for ergogenic and health 
benefits of ephedra-containing PWS, a concerning number of adverse effects, led to its 
prohibition in 2004 by the FDA (Gurley, Steelman, & Thomas, 2015). The range of reported 
adverse events included cardiac arrhythmias (Dwyer, Allison, & Coates, 2005; Haller, 2000), 
myocardial infarction (Haller, 2000; Smith et al., 2014), strokes (Bouchard et al., 2005; 
Haller, Jacob, & Benowitz, 2002; Holmes & Tavee, 2008), seizures (Kockler, McCarthy, & 
Lawson, 2001; Moawad, Hartzell, Biega, & Lettieri, 2006) and rhabdomyolysis (Rhidian, 
2011; Stahl, Borlongan, Szerlip, & Szerlip, 2006). Due to the complex nature of the PWS 
formulations, it was difficult to directly link ephedra to these adverse effects, although an 
increasing number of emergency medicine cases reported were strongly correlated with use of 
ephedra-containing PWS.  
 
Figure 1 Photograph of Ephedra Sinica 
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1.1.1.2 Acacia rigidula (AR) 
 
The Acacia genus contains over 50 different species containing various amines and alkaloids. 
Acacia rigidula (AR) grows predominantly in the southern regions of Texas, USA. Based on 
the current literature, there have not been any reports of its use in traditional medicine. A 
study in 1998 has reported the presence of a phenethylamine-type compound, N-methyl-β-
phenethylamine (N-MePEA) and N-methyltyramine (N-MeTYR) (Clement, Goff, & Forbes, 
1998).  
In recent years, AR extracts have been commonly listed on PWS labels as stimulatory 
ingredients. The increased use and lack of information on AR extracts in PWS led the U.S. 
FDA to establish a method for the quantitative determination of biogenic amines, 
phenethylamine (PEA), tyramine and tryptamine derivatives (Pawar, Grundel, Fardin-Kia, & 
Rader, 2014).  The study conducted by Pawar et al. on AR analysis contrasted their findings 
with those of Clement et al. and found that 20 of the 21 supplements tested had high amounts 
of PEA. Importantly, PEA does occur naturally in AR or extracts thereof. Worryingly, β-
methylphenylethylamine (BMPEA), a positional isomer of methamphetamine was found in 9 
of the 21 samples with amounts ranging from 963 µg/g to 60,500 µg/g and it was likely to 
have been misidentified as amphetamine in 1998. There is no safety data on the biological 
effect of the BMPEA in humans (Pawar et al., 2014). Since this study was concluded, AR-
containing products were banned in 2015 by both the FDA and TGA on the basis that 
products containing AR have not previously been consumed as a food and lacked substantial 
safety evidence (Upadhyay, 2014).   
1.1.1.3 Citrus aurantium (CA) 
 
Citrus aurantium (CA) is known common as names such as bitter orange, sour orange, Seville 
orange, chongcao, and neroli. The plant has its origins in tropical Asia and has been used in 
traditional Chinese medicines. The main volatile components in the flowers and peel of CA 
are the flavonoids, hesperidin and naringin whereas the non-volatile alkaloid components 
include synephrine, octopamine and tyramine (Pellati, Benvenuti, Melegari, & Firenzuoli, 
2002). Synephrine acts as an α-adrenergic agonist, with some β3-adrenergic agonist properties 
(Astrup, 2000).  β3- receptors are found mainly on adipose tissue, and regulate lipolysis and 
thermogenesis (Ferrer-Lorente, Cabot, Fernández-López, & Alemany, 2005). This was the 
basis for the purported CA efficacy as a weight-loss agent. Animal studies have shown that 
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synephrine significantly reduced food intake in rats (Verpeut, Walters, & Bello, 2013). On the 
other hand, pilot studies conducted by Greenway et al. failed to demonstrate a significant 
difference between the treatment and control groups for food intake, appetite ratings or body 
composition (Greenway et al., 2006).  To date there is a lack of evidence to support the use of 
CA in appetite control and weight loss in humans (Onakpoya, Davies, & Ernst, 2011). The 
pharmacological effects will be further discussed later in this chapter.  
   
 
Figure 2 Photograph of Citrus aurantium 
 
1.1.2 Current Regulations of PWS in Australia (TGA) Compared to Overseas 
 
Pre-workout supplements are considered complementary medicines, under the Therapeutic 
Goods Act of 1989 as it contains herbal material (i.e. plant extracts) (Therapeutic Goods 
Administration, 2013). The Therapeutic Goods Administration (TGA) is a sub-group of the 
Australian Government Department of Health responsible for regulating the supply and export 
of therapeutic goods. These goods include prescription medicines, complementary medicines, 
vaccines, vitamins and minerals (including supplements) medical devices, blood and blood 
products. A complementary medicine is defined by the TGA as a therapeutic good consisting 
wholly or principally of 1 or more designated active ingredients, each of which has a clearly 
established identity and a traditional use. The TGA employs a risk-based (watch and wait) 
approach to regulation of complementary medicine whereby products containing herbal 
materials that present a higher risk, must be registered with the Australian Register of 
Therapeutic Goods (ARTG). Lower-risk substances may be found on the TGA’s registry of 
‘Substances which can be used as a Listed Medicine’. These may be classified as active, 
component or excipient and may have further restrictions on their use such as that mentioned 
for caffeine and synephrine.  
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The TGA also conducts post-market regulatory monitoring of products to ensure safety for 
consumption via a two-tiered system whereby registered medicines are tested by the TGA for 
quality, safety & efficacy whereas listed ingredients are only tested for quality and safety not 
efficacy. Where an Australian-made product produces unexpected or undesirable side effects, 
the product may be reported to the TGA. When the TGA receives a report from a consumer of 
an adverse effect following consumption of a PWS, for example, they will conduct an 
investigation. This includes sending a sample to a laboratory for a quantitative component 
analysis (TGA, 2016b) which, depending on their workload, can take up to 6-12 months. The 
TGA may, following their investigations, consider enforcing the discontinuation of the 
product (that is, if the company and or product still exists). It is estimated that only a fraction 
of adverse effects are ever reported and often reports are made directly to the manufacturer. In 
the latter case, there is a disincentive for the company to relay the report to the TGA.   
Since the TGA also regulates the importation of PWS and ingredients therein, products 
entering Australia are subject to scrutiny upon arrival into the country. In reality, due to 
limitations on staff and/or time, only the larger import quantities are usually checked. 
However, with the increased popularity of ‘online stores’ consumers may not necessarily 
know the origin of the product. TGA scrutiny can be side-stepped by having small product 
orders mailed directly to consumers. The TGA regularly posts updates on adulterated and 
discontinued products (TGA, 2016a).  However, this method of reporting may be inefficient 
as general consumers do not necessarily know where to look for such information. 
In Australia, medicines, poisons and therapeutic goods are regulated under the Therapeutic 
Goods Act (1989), and in particular, the Poisons Standard (November 2016) being the 
legislative instrument.  Within this framework substances are classified into schedules which 
help determine how medicines and poisons are made available to the public 
(https://www.legislation.gov.au/Details/F2016L00036) (Gill, 2016). Schedules are ranked 
according to the level of regulatory control required such that Schedule 1 (medicines that are 
not in use), Schedule 2 (pharmacy medicines) to Schedule 10 (dangerous substances that are 
prohibited for sale) (Figure 3).  
| | | | | | | | | | 
1 2 3 4 5 6 7 8 9 10 
 
Figure 3 Scheduling of medicines and poisons implemented by the TGA of Australia. Comprehensive breakdown and 
explanation is shown in Appendix 9. 
Prescript
-ion only 
medicine 
Not in 
use  
Pharmacy 
medicine 
Pharmacist 
only 
medicine  
Caution  Poison  Dangerous 
Poison  
Controlled 
Drug  
Prohibited 
Substance  
Prohibited 
for sale  
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Amphetamine is classified as a Schedule 8 substance (drugs of addiction) while ephedrine, for 
example, a Schedule 4 substance (restricted prescribed substance) (Australian Government 
Department of Health, 2015) (Gill, 2016).  
Synephrine is classed as a Schedule 4 substance with a recommended daily dose (RDD) of 30 
mg. A therapeutic dose in treatment of hypotension, as defined by the Poison Standard of 
Australia was about 300 mg daily and there was little evidence of harmful effects at 30 mg in 
a daily dose (Gill, 2015). The scheduling of synephrine was considered in 2002 when CA 
extracts were first advertised with manufacturer’s claims of enhanced metabolite support and 
weight loss (National Drugs and Poisons Schedule Committee, 2003). At that time 
approximately 1000 products listed in the ARTG containing synephrine ranging from 2 µg to 
over 31 mg.  
Octopamine was banned as an ergogenic aid in competitive sports by the World Anti-Doping 
Agency (WADA) in 2002 however, despite this; octopamine has yet to be considered for 
scheduling due to a lack of reported adverse effects. Octopamine is present in lower 
concentrations compared to synephrine in CA extracts. Octopamine is been shown to act as a 
monoamine neurotransmitter in invertebrates, but its role in vertebrates is uncertain (Roeder, 
1999). Many dietary supplements (including PWS) that contain octopamine have been shown 
to raise blood pressure (Haller, Benowitz, & Jacob, 2005). Tyramine, on the other hand, has 
not been subject to a ban by WADA nor any other sporting associations.  There are currently 
no legislative restrictions relating to either tyramine or octopamine.  
In 2011, Health Canada conducted a health risk assessment (HRA) report on the use of 
synephrine, octopamine and caffeine as well as the peel of CA. Like the TGA, Health Canada 
also employs a risk-based approach in evaluating safety and efficacy of products. Evidence 
for the results derived from a single six-week study which concluded that at the maximum 
RDD of 320 mg caffeine and 40 mg synephrine participants did not show harmful effects 
(Colker, Klalman, Torina, & Perlis, 1999).  The study involved 20 subjects with a body-mass 
index of >25 kg/m
2
 where they were sub-divided 3 groups: group A, ingested 975 mg CA 
extract, 528 mg caffeine and 900 mg of St. John’s wort; group B was a placebo; and group C 
served as a control without any supplement intervention. The diets and exercise sessions were 
controlled and the amount of body weight change was measured. This study had a few 
limitations, one, was the small sample size of overall patients per group. 20 individuals is a 
miniscule representation of the human population.  Besides that, there was a statement on 
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conducting laboratory tests within the results of their study but there was no further discussion 
or description on the vital signs of their patients during the study.  Apart from that, there were 
no discussions on the variability of the health of the individuals apart from a body-mass index 
of >25 kg/m
2
. The study would have been improved had specific exclusion criteria for their 
patients been included. Based on this study however, the HRA report concluded that a dose of 
up to 50 mg/day p-synephrine was not likely to trigger a cardiovascular event. In addition, 
they concluded that, for healthy individuals, the use of less than 40 mg/day of synephrine in 
conjunction with 320 mg/day of caffeine was classified as low risk. It should be noted that 
this health risk assessment was funded by the company and conducted by Stohs, a known 
advocate and senior scientist for AdvantraZ® (CA extract) (Bloomberg Business, 2015; 
Stohs, et al., 2011; Stohs, Preuss, & Shara, 2011, 2012).  
In contrast to Canada’s safety assessment of PWS, in 2013, the Federal Institute for Risk 
Assessment (BfR) of Germany assessed the risks of PWS and weight-loss supplements 
containing both synephrine and caffeine. The BfR looked at the quantities of synephrine and 
caffeine contained therein and noted a high level of variability in suggested doses between 
products. As both these constituents are known to affect the cardiovascular system, their 
combined consumption posed a higher risk to consumers. The German BfR established a 
maximum safe dosage of synephrine of 25.7 mg (The Federal Insitute for Risk Assessment, 
2013). Since CA extracts also contain other stimulants aside from synephrine, such as 
octopamine and tyramine, further cardiovascular effects such as increased heart rate and blood 
pressure would be expected to occur. 
According to the BfR, many of the products assessed contained more than the maximum safe 
dosage of 25.7 mg thereby breaching the regulation. On this basis, the BfR classified sports 
supplements, such as PWS as unsafe for human consumption. Moreover, since the target 
market was likely individuals undergoing physical exertion, the added strain on the 
cardiovascular system was higher. Moreover, adverse effects from the use of weight-loss 
supplements containing CA would be amplified and pose a greater risk for an overweight, 
ageing population with likely pre-existing cardiovascular problems (The Federal Insitute for 
Risk Assessment, 2013). 
Caffeine, another prominent inclusion in PWS, is the only methylxanthine subject to specific 
product labelling requirements – the details of which vary depending on country of 
manufacturing origin. In the US, for example, only added caffeine must be listed as an 
ingredient while in Australia products containing caffeine are required to state the amount and 
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also carry a warning. Currently no recognised health-based guide for acceptable caffeine 
intake exists, although Food Standards Australia and New Zealand (FSANZ) recommends a 
maximum daily caffeine limit in caffeinated foods or beverages of 95 mg/day for children 
(aged 5-12) and 210 mg/day for adults (approximately 3 cups of coffee per day) ( Smith et al., 
2000), In Australia however, the composition of PWS and other dietary supplements, 
classified as complementary medicines, is regulated by the Therapeutic Goods 
Administration.  
A recent review on caffeine toxicity suggested that undeclared herbal components in most 
supplements could expose consumers to an increased risk of caffeine toxicity (Musgrave, 
Farrington, Hoban, & Byard, 2016). Since there is a degree of overlap in the stimulatory 
effects of caffeine and dimethylxanthines (DMX), the total effect is likely additive (Fredholm, 
2011). These combined circumstances make it difficult for individuals to keep track of their 
caffeine intake which may lead to potential adverse effects from overconsumption. Such 
increased PWS consumption beyond athletes and fitness enthusiasts into recreational use by 
the general population (Gibson, 2014), and concomitant the increased adverse health reports 
may result in more stringent caffeine content/ labelling requirements leading to an increased 
demand for analysis of products. 
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1.2 Structural and Chemical Properties of Key Stimulants in PWS 
 
The two key stimulant groups within PWS of interest for this research are the amphetamine-
like compounds within CA, synephrine, octopamine and tyramine; and caffeine with its 
dimethyl derivatives. 
1.2.1 Amphetamine-like Compounds 
 
Table 2 summarises the key physicochemical properties of our compounds of interest and 
compares their similarity to amphetamine and ephedrine. The compounds mentioned in the 
table can be classed as substituted phenethylamines where the variations in molecular bonding 
results in different chemical and physical properties. Like amphetamine and ephedrine, 
synephrine is a phenethylamine however distinctly containing one phenol hydroxyl group 
absent in the banned compounds. In fact, they are structurally in between the natural 
catecholamine and the banned amphetamine compounds. Synephrine contains a total of two 
hydroxyl groups, positioned in B (ring) and W (side chain), as well as a methyl group on 
position Y. This correlates with its high degree of polar surface area. Octopamine has 
similarly substituted hydroxyl groups at position B and W but lacks the methyl group on 
position Y (on the amine nitrogen). Tyramine has a hydroxyl group substituted only on 
position B. As expected all the compounds have basic pKa values (between 8.55 for and 10.4 
for tyramine).  
The similarity in structure of these compounds have led many researchers to hypothesise 
similar pharmacological outcomes (Broadley, 2010; Chen et al., 1981; Clement et al., 1998; 
Gibbons, 2012; Liles et al., 2006; Oberlender & Nichols, 1991; Pawar et al., 2014). 
Synephrine and octopamine, predominantly exists as the naturally occurring p-synephrine and 
p-octopamine, with the hydroxyl group located on the para-position on the benzene ring of the 
molecule (Mattoli et al., 2005; Pellati, et al., 2005; Rossato et al., 2010).  
  
 
1
5
 
 
 
 
 
 
Table 2 Chemical properties of different amphetamine-like compounds 
Compound Formula MW A B W X Y Z logP pKa 
Polar surface 
area (PSA) (Å)2 
Rotatable 
bonds 
Hydrogen 
bond donors 
Hydrogen bond 
acceptors 
Stereo-
centres 
Synephrine C9H13NO2 168.2 H OH OH H CH3 H 1.98 9.46 40.46 2 2 2 1 
Tyramine C8H11NO 137.2 H OH H H H H 0.86 10.41 46.20 2 3 3 1 
Octopamine C8H11NO2 153.2 H OH OH H H H -0.59 9.64 66.48 2 3 3 1 
Epinephrine C9H13NO3 183.2 OH OH OH H H H -0.54 8.55 72.72 3 4 4 1 
Nor-epinephrine C9H13NO3 169.2 OH OH OH H H H -1.26 8.58 86.70 2 4 4 1 
Amphetamine C9H13N 135.2 H H H CH3 H H 1.76 9.90 26.02 2 1 1 1 
Ephedrine C110H15NO 165.2 H H OH CH3 H CH3 1.13 9.65 32.3 3 2 2 2 
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1.2.2 Caffeine and Dimethylxanthines  
 
Methylxanthines such as, caffeine (1,3,7-trimethylxanthine), theobromine (3,7-
dimethylxanthine), and theophylline (1,3-dimethyxanthine) are distinguished by 
variations in the number and position of methyl groups around the xanthine ring 
(coupled pyrimidinedione and imidazole ring structure) (Talik, Krzek, & Ekiert, 2012) 
shown in Table 3. While many methylxanthines are of plant origin and found in foods 
and beverages such as coffee, teas, yerba mate and cocoa, paraxanthine (1,7-
dimethylxanthine), is a metabolic product of caffeine degradation in humans and is not 
found in plants (Orru et al., 2013).  
 
 
Table 3 Chemical properties of caffeine and DMX 
Compound Formula MW A B C log P pKa 
Polar 
Surface 
area 
(PSA) 
(Å)
2
 
Caffeine C8H10N4O2 194.2 CH3 CH3 CH3 -0.1 14 58.4 
Theobromine C7H8N4O2 180.2 H CH3 CH3 -0.8 9.9 67.2 
Paraxanthine C7H8N4O2 180.2 CH3 H CH3 -0.2 10.76 67.2 
Theophylline C7H8N4O2 180.2 
 
CH3 CH3 H 0 8.81 69.3 
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1.3  Pharmacological Properties of Key Stimulants in PWS. 
1.3.1 Pharmacodynamics of The Adrenergic Amines in CA 
 
Synephrine is commonly identified as the active component of CA and acts primarily as 
an α-adrenergic receptor (ARs) agonist (de Oliveira et al., 2013; Pellati et al., 2002). 
Functional studies showed that synephrine had agonist activity specific on the α 1A-AR 
subtype but showed some antagonism for the pre-synaptic α2A and α 2C-ARs present in 
nerve terminals (Ma et al., 2010). Other studies that tested the binding affinities of 
synephrine reported that p-synephrine had overall lower affinity for αARs compared to 
m-synephrine (Brown et al., 1988; Hibino, Yuzurihara, Kase, & Takeda, 2009; Hwa & 
Perez, 1996). The presence of hydroxyl groups at the β-carbon (position W in Table 2 
Chemical properties of different amphetamine-like compounds) increases its polarity 
and thus reduces its ability to cross the blood brain barrier (BBB). This would decrease 
the likelihood of synephrine affecting central nervous system (CNS) activity (Brunton, 
Lazo, & Parker, 2005). 
Synephrine, like ephedrine, is also known to act as a β-adrenoceptor (AR) agonist, 
specifically on -AR (Arch, 2002; Carpene et al., 1999) which can result in increased 
lipolysis and basal metabolic rate producing the net effect of weight loss (Haaz et al., 
2006). To date there is little clinical evidence to support synephrine’s thermogenic 
properties. A study in mice, conducted in 2008, demonstrated that neither CA extracts 
(5 g/kg and 10 g/kg standardised to contain 2.5% synephrine) nor an orally-
administered dose of p-synephrine (300 mg/kg) significantly increased body 
temperature (Arbo et al., 2008). Arbo et al. (2009) also showed that there was a lower 
weight gain in rats that were administered 30 and 300 mg/kg of p-synephrine for 28 
consecutive days compared to the controls. However, these results may not be 
necessarily transferable to humans as a double blind, placebo controlled trial in humans 
involving a dietary supplement containing 21 mg of synephrine and 304 mg of caffeine 
coupled with an exercise regime did not significantly increase thermogenic effect during 
exercise (Haller et al., 2005).   
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Synephrine is a chiral molecule and it exists in a S (+)-form and a R (-)-form. A study 
by Jordan et al., determined that S (+)-synephrine was 1 to 2 orders of magnitude less 
active than the R (-)-synephrine on β1-adrenoceptors in guinea-pig atria (Jordan, 
Midgley, Thonoor, & Williams, 1987). Brown et al., described the level of activity of S 
(+)-synephrine to be less active than the R (-)-synephrine on the α1-adrenoceptors on a 
rat aorta. It should be noted that these studies may not appropriately represent the 
receptor binding properties of synephrine enantiomers in humans. The determination of 
the enantiomeric composition of pharmaceuticals and nutraceuticals is important to 
understand the pharmacology of the synephrine component of CA-containing PWS. 
There are no current studies published that determine the specific synephrine 
enantiomers present in CA extracts or CA-containing PWS. 
Octopamine was first identified in the posterior salivary glands of an octopus (Octopus 
vulgaris) from which its name derives. It is also present in plants, invertebrates and 
vertebrates (David & Coulon, 1985) as well as plants such as the fruit of CA. It plays a 
significant role in neurotransmitter activity for invertebrates similar to the physiological 
activity of adrenaline in mammals (Roeder, 1999). Non-naturally occurring m-
octopamine is the most potent amongst its isomers followed by p-octopamine, which is 
10-fold less potent than m-octopamine 
Octopamine was found to act as a β1-adrenergic receptor agonist (EC50 of 3.1 ± 0.4µM 
(Kleinau et al., 2011)) as well as a β3-adrenergic receptor agonist (present in adipocytes 
(Carpene et al., 1999)). Moreover, there was no apparent β2-receptor binding up to a 
concentration of 6.7 µM while allosterically inhibiting other β2 agonists such as 
isoprenaline. m-Octopamine, in particular, is also an α-adrenergic receptor agonist that 
is suggested to be one hundredth of the potency of noradrenaline to increase blood 
pressure (Fregly, Kelleher, & Williams, 1979) due to its higher α1 adrenergic receptor 
affinity (6-fold less than noradrenaline) compared to α2-adrenergic receptor affinity 
(150-fold less potent than noradrenaline) (Brown et al., 1988). 
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Tyramine can be naturally found in common dietary sources such as chocolate, aged 
cheese, aged meat and certain fruits and vegetables as well as in as alcoholic beverages. 
(Ziegleder et al.,1992). Similar to noradrenaline, tyramine indirectly acts as a 
sympathomimetic amine. These amines have weak actions on adrenoceptors, but are 
transported by the neuronal noradrenaline transporter (NET). In the nerve terminal, the 
amines are taken up into synaptic vesicles by the vesicular monoamine transporter 
(VMAT) to release noradrenaline into the cytosol.  
The established mechanism for vascular effects of trace amines is that they behave by 
indirectly acting as sympathomimetic amines by stimulating the release of 
noradrenaline from sympathetic neurons (Broadley et al., 2009). To support the indirect 
mechanism of action of tyramine and other trace amines, reserpine treatment was used 
on isolated tissue and in vivo. Reserpine is a drug used for the control of high blood 
pressure by reducing the amount of noradrenaline from vesicular stores of sympathetic 
neurons. The treatment reduces the responses to sympathetic nerve stimulation and the 
indirect effects of trace amines (Burn & Rand, 1958).  In rats, pressor effects due to 
ephedrine were caused by a direct effect on α-adrenoceptors, whereas tyramine showed 
indirect stimulation (Liles et al., 2006). The effects of directly acting sympathomimetic 
amines, such as noradrenaline and isoprenaline, are increased by chronic treatment with 
reserpine, due to the up regulation of the adrenoceptors (Chess-Williams, Grassby, 
Broadley, & Sheridan, 1987). Reserpine causes the release and breakdown of 
noradrenaline (NA) as well as depleting neurons of NA. Thus, no response to the 
indirectly acting sympathomimetics after reserpine could be obtained. Reserpine 
depletes the neurones of noradrenaline which results in no downregulation of receptors. 
Hence, the increase in receptor activity would increase the response of directly acting 
drugs (Chess-Williams et al., 1987).  
Synephrine, octopamine and tyramine can be described as trace amines which interact 
with trace amine associated receptors (TAARs).  The initial discovery of a new family 
of G protein-coupled receptors (GPCRs) was based on the pharmacological profile of its 
prototypical receptor, trace amine-associated receptors (TAAR1), this set of GPCRs 
was later termed TAARs (Borowsky et al., 2001).  These receptors are expressed in 
both rats and humans, with only slight variations in response to drugs, due to their low 
homology (Wainscott et al., 2007). The receptors are intracellular in contrast to 
adrenergic receptors, which are located on the cell surface membrane (Xie et al., 2008). 
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The TAAR1 receptor has structural similarities to rhodopsin/ β-adrenergic receptor 
family that responds to tyramine and β-phenylethylamine (Barak et al., 2008). The 
amount of data on the receptor binding properties of synephrine and octopamine are 
currently limited. 
1.3.2 Pharmacokinetics of Adrenergic Amines in CA 
 
Interestingly trace amounts of synephrine are produced in humans, possibly as a 
degradation product of the catecholamines – to which they share structural similarity. 
(Watson et al., 1990). A portion of cytosolic noradrenaline is deaminated by 
monoamine oxidases (MAO) whereas some is released into synaptic cleft to act on post-
synaptic receptors. MAO inhibitors (MAOI) prevent inactivation of the transmitter 
displaced from the vesicles within the terminal. MAO inhibition enhances the action of 
tyramine as it is normally degraded by gastrointestinal tract and liver MAO before 
entering the systemic circulation. The occurrence of dietary tyramine-provoked 
hypertensive crisis is a well-known interaction associated with irreversible MAO-A 
inhibition (Chen , Swope, & Dashtipour, 2007).  
Referring to metabolic pathways, synephrine is not degraded by catechol-o-
methyltransferases. The substitutions on the α-carbon block oxidation by MAO. 
However, synephrine lacks an α-carbon ligand resulting in degradation via MAO. The 
oxidation of synephrine and octopamine by MAO results in the production of p- and m-
hydroxymandelic acid as well as hydrogen peroxide which could result in oxidative 
stress (Grandy, 2007) (Figure 4). The plasma half-life of m-synephrine is two to three 
hours (Haaz et al., 2006). Experiments show synephrine undergoes phase 2 metabolism, 
glucuronidation and sulfation (Ibrahim, Couch, Williams, Fregly, & Midgely, 1985). A 
study in 1983 that investigated the composition of urine after oral ingestion of 
synephrine found that 47% sulphated synephrine, 30% hydroxymandelic acid, 12% 
conjugated synephrine and 6% hydroxyphenylglycol sulphate was produced (Ibrahim et 
al., 1985).  Another study, investigating enantiomeric differences for synephrine 
showed that 20-50% of synephrine ingested was excreted in conjugated R (-)-
synephrine form, and 10% as S(+)-synephrine (Kusu, Matsumoto, Arai, & Takamura, 
1996).  
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In-vitro studies have shown that both m- and p-synephrine isomers are taken up by 
Caco-2 cells, suggesting that they can be absorbed by the gastrointestinal tract at an 
equal rate (Rossato et al., 2010). However, poor bioavailability of synephrine has been 
observed in a human study involving the oral ingestion of 5.5 mg of synephrine. The 
peak plasma concentration of the subjects was less than 1 ng/mL (Haller et al., 2005).  
 
Figure 4 The degradation pathway of trace amines. MAO represents the monoamine oxidases; ADH represents 
the aldehyde dehydrogenase; PNMT represents the phenylethanolamine-N-methyl transferase  
CA extracts contain flavonoids, specifically 6’, 7’-di-hydroxy-bergamotin, a P4503A4 
selective antagonist (Fugh-Berman & Myers, 2004). As cytochrome P4503A4 
metabolises a majority of existing drugs, for example, MAOI antidepressants, it is not 
advisable to also take CA-containing PWS (Fugh-Berman & Myers, 2004). The use of 
MAOI would impair the metabolism of synephrine and potentially cause hypertension 
due to its prolonged vasoconstriction (Grandy, 2007). 
 
 
ADH 
ADH 
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1.3.3 Pharmacology of Caffeine and Dimethylxanthine Derivatives 
 
Reports that caffeine increases endurance performance and/or recovery (Hodgson 
Randell, & Jeukendrup, 2013; Leveritt et al., 2012; Santos et al., 2014; Stadheim et al., 
2013), likely gave further impetus to caffeine being marketed as an ergogenic aid in 
PWS. Caffeine consumption and the increased risk of cardiovascular diseases depend 
on a number of factors such as the variability of population, dose, confounding factors 
and/or low statistical power of the studies (Zulli et al., 2016). Since there is overlap in 
the stimulatory effects of caffeine and DMX, the total effect is likely additive 
(Fredholm, 2011). These combined effects make it difficult for individuals to keep track 
of their total stimulant intake which may lead to potential adverse effects from stimulant 
overconsumption. 
Caffeine has a dose-dependent effect on the CNS which includes mood enhancement, 
wakefulness, insomnia, seizures and anxiety. These CNS effects derive from the 
antagonism of the adenosine receptors that are present in the brain. However, caffeine’s 
haemodynamic effects are attributed to the antagonism of the adenosine receptors, A1 
and A2 (Figure 5). This includes increased heart rate, elevated blood pressure and 
peripheral and coronary vasoconstriction (Benowitz, 1990). Caffeine is also known to 
inhibit cAMP-mediated phosphodiesterase which leads to the accumulation of the 
second messenger; cyclic adenosine monophosphate (cAMP) enhances the effect of 
biogenic amine stimulation at adrenergic receptors. The mobilization of intracellular 
calcium by activation of γ-aminobutyric acid (GABA) neurotransmission (Riksen, 
Rongen, & Smits, 2009).  
Caffeine has been shown to decrease blood flow to the cerebral, mesenteric and hepatic 
system. It also produces a diuretic effect via inhibiting antidiuretic hormone (ADH) 
which increasing glomerular filtration which results in higher water and sodium 
excretion (Benowitz, 1990). Higher doses of 400 mg/day caffeine would cause 
bronchodilation, hypokalaemia from the movement of intracellular calcium, 
hyperglycaemia and lipolysis (Monteiro, Alves, Oliveira, & Silva, 2016). Chronic use 
of caffeine with daily doses exceeding 300 mg can lead to a dose-dependent tolerance, 
which increases the risk of hypokalaemia which may cause ventricular arrthymias (Shi 
et al, 1990; Goldfarb, 2014).  
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Figure 5 (Left) adenosine receptor binding to adenosine which causes nervous activity to slow down. (Right) 
presence of caffeine that acts as an adenosine antagonist that result in an increased nervous activity (Pang & Ko, 
2006)  
Caffeine is recognised to potentiate the cardiovascular and CNS effects of other 
stimulants which contain plant-derived α- and β-adrenergic agonists such as those from 
the Ephedra species (ephedrine, pseudoephedrine, norephedrine and methylephedrine) 
(Brown , Porter, Ryder, & Branch, 1991; Haller, Jacob, & Benowitz, 2004; Lake, 
Rosenberg, & Quirk, 1990). 
TP and TB are present in coffee, tea and cola beverages albeit in lower concentrations 
than caffeine. However, PX is the main metabolite of caffeine in humans and is not 
naturally found in plants (Orru et al., 2013). TP is often used as a bronchodilator but its 
use is restricted by a narrow therapeutic range of 5-20 µg/mL (Mitenko & Ogilvie, 
1973), where adverse effects are known to occur above 20 µg/mL. TB has fewer CNS 
effects than caffeine and TP, but has been reported to be a potent cardiovascular 
stimulant (Monteiro et al., 2016).  
The physiological effects of PX are not as well explored but it may increase skeletal 
muscle contraction (Hawke, Allen, & Lindinger, 2000). Orru et al., showed that in rats, 
PX has a stronger locomotor activating effect than caffeine or the two other main 
metabolites of caffeine, TP and TB. As previously described for caffeine, the locomotor 
activating doses of PX more efficiently counteract the locomotor depressant effects of 
an adenosine A (1) than an adenosine A (2A) receptor agonist. Ex vivo experiments 
demonstrated that PX, but not caffeine, can induce cGMP accumulation in the rat 
striatum. These findings suggest that the inhibition of the cGMP-preferring 
phosphodiesterase (PDE) is involved in the locomotor activating effects following the 
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acute administration of PX (Orru et al., 2013). There was a considerably lower amount 
of attention given to PX for efficacy research compared to caffeine.  
The challenge associated with PWS quantitation include content inconsistency, 
labelling inadequacies, product adulteration and contamination, combination of plant 
extracts with little evidence of safety. A study in 2013 found that caffeine quantity 
varies considerably between brands of ephedra-free dietary supplements sold in the 
USA (Kole & Barnhill, 2013). Furthermore, some products fail to provide an adequate 
indication of the exact quantity of caffeine in the product (Foster et al., 2013). This 
would potentially be harmful to users that metabolise caffeine at a slower rate or who 
may be prescribed stimulants (i.e. Adderall® and Ritalin®) or MAOI. 
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1.4 Quantitative Analysis of Components in PWS 
 
Chromatography is a physical method of separation which exploits a compound’s 
polarity. Analytes of interest partition between two phases, stationary or mobile, 
according to their affinity for that phase (Heftmann, 2004). Chromatography can be 
categorised by either the type of physical chromatographic bed (column or planar); the 
choice of mobile phase (either gas or liquid); or the separation mechanism (ion-
exchange, size-exclusion, solubility etc.). Gas chromatography (GC), pioneered by 
Martin & Synge in 1941, is suitable for separating complex mixtures of volatile 
components, however derivatisation is often necessary to volatilise non-volatile 
analytes. In addition, highly polar compounds (such as amines) are not easily analysed 
with GC. Liquid chromatography (LC), on the other hand, has no sample volatility 
issues, is suitable for polar compounds and faster analyses are possible with generally 
shorter columns.  
High Pressure Liquid Chromatography (HPLC) instruments are capable of pumping 
solvent to a limit of around 5,000 psi depending on system robustness. HPLC, was 
introduced in the 1980s, is now one of the most widely used analytical instrumental 
techniques (Heftmann, 2004). Ultra-high Pressure LC (or UPLC) systems are capable of 
achieving higher pressures (up to around 15,000 psi) resulting in fast run times and 
higher resolution, However UPLC systems are understandably costlier. In LC analyses, 
normal-phase separation uses a polar stationary phase chemistry, whilst reverse-phase 
employs a packing material coated usually with a non-polar, hydrocarbon substance 
such as phenylhexane or octadecane (C18). The latter is preferable for a wider range of 
polarity compounds and is less expensive in terms of solvent usage creating less organic 
waste. Therefore, for the separation of the analytes of interest in this study – a set of 
charged amines as well as non-polar components, reversed-phase (RP-HPLC), was 
selected as the ideal choice keeping in mind instrumentation limitations.  
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Figure 6 depicts a typical HPLC system consisting of mobile phase pump, a degasser 
which removes gasses from solvent, an injector, the column and a detector.  
 
Figure 6 Schematic of a generic HPLC set up 
The most common mobile phase for modern HPLC is generally a mixture of water, 
methanol or acetonitrile. The percentage of these components is held constant 
throughout the entire run is termed an isocratic elution protocol. When the composition 
of the mobile phase changes over the course of the run, however, it is called a gradient 
elution profile. Increasing the organic component generally increases the elution 
strength of the mobile phase. Additives to the mobile phase such as buffers or 
tetrahydrofuran (THF) are often required to improve the analyses. A more detailed 
description of these and the theory of chromatography will be presented in Chapter 2.  
Once separated, analytes exit the column and enter the detector. In the case of a UV-
absorbing analyte, such as amphetamine-like compounds and xanthines in this study, a 
UV detector is employed. Selecting the most suitable wavelength for analysis is not 
always as simple as determining the maximum wavelength (λmax) especially in multi-
component analyses due to co-elution issues.  There are many different types of 
detectors available for HPLC analysis – the choice of which may depend on availability, 
although certain detectors are more suitable for some purposes over others. 
Electrochemical detectors are highly sensitive and based on detecting electrical currents 
generated from a reduction/oxidation of the analyte. They are often employed in 
catecholamine and neurotransmitter analyses. UV detectors generally require a 
chromophore for analyte detection such as an aromatic ring or conjugated double bond 
system. Photodiode array detectors (PDA) are UV-based detectors but differ from the 
simpler UV detectors by the position of the beam splitter. By placing the splitter after 
the sample, all wavelengths can be detected simultaneously which provides a wealth of 
spectral data. This is advantageous especially if the ideal wavelengths are not known. 
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The detectors mentioned so far are considered non-destructive in nature, thus samples 
may be collected for further analysis. Mass spectrometry (MS), though a destructive 
technique is used to determine the mass of the analyte (up to 4 decimal places in some 
instances) and can unambiguously confirm structure. In MS, analytes are volatilised on 
entry to the detector, followed by ionisation and fragmentation. Charged ions then travel 
towards the mass detector via a magnetic field which deflects the ions such that the 
lighter species travel on a different trajectory to the heavier ones thus forming the basis 
of separation. A single set of magnets is termed a ‘single quadrupole’ instrument. 
Combining multiple sets of magnets in series (for example, a ‘triple-quadrupole’ 
instrument) facilitates vast improvements in analytical power. The key to structure 
determination in this technique lies in the fragmentation of parent sample ions. Unique 
fragmentation patterns for individual compounds become like fingerprints then as a 
means of structure confirmation. A comprehensive review of HPLC detectors is beyond 
the scope of this thesis. Scott presents an excellent though not recent review on 
chromatographic detection techniques (Scott, 1996). Thus the combination of LC-MS is 
a powerful tool for both separation and detection of analytes in a sample matrix.   
A typical chromatogram is a plot of an intensity of absorption versus retention time. 
Ideally each analyte peak should be sharp and symmetrical and completely resolved to 
baseline with no obvious co-elution issues. Achieving this however involves a 
considerable amount of trial and error. Optimisation refers to the process of determining 
the most ideal conditions that produce the best separation and is often a balance in terms 
of time and cost efficiency. When developing HPLC methods from scratch, many 
factors contribute to the final optimised method including column 
chemistry/parameters, mobile phase selection, pH, column temperature, flow rate, 
gradient optimisation, purity of samples, sample matrix etc.  Additional chemicals, or 
modifiers, are often included in HPLC analyses and enhance retention and/or 
separation. The type of solvent or modifier used can greatly influence the selectivity and 
retention factor for the analyte in question (Dolan, 2008)  
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Sample preparation is often required to remove contaminants in complex matrices such 
as PWS. The two sample preparation methods that will be explored in Chapter 2 are 
liquid-liquid extraction (LLE) and solid phase extraction (SPE). LLE involves the phase 
separation of an analyte between two immiscible liquids. These typically comprise an 
organic solvent, such as dichloromethane or ethyl acetate and an aqueous phase. For 
basic components, such as the amines in this analysis, the polarity of the molecules is 
manipulated by adjusting the pH of the aqueous phase to firstly pKa +2 to force them 
into the organic phase and later pKa -2 to allow phase transfer back into the aqueous 
phase for further analysis. SPE is a separation process by which the compounds of 
interest in a liquid mixture are immobilized on a silica-based packing material before 
being eluted off. SPE has the advantage of reducing the amount of sample required for 
analysis as well as the amount of solvent used in the process. SPE has a large variety of 
sorbent material, which allows better matching of the phase for the analytes. Therefore 
it was possible to develop a procedure isolating a larger range of compounds.  
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1.4.1 HPLC Analysis of Active Components of CA in Dietary Supplements  
 
Several studies have been conducted on the determination of phenethylamine alkaloids 
present in CA-containing dietary supplements. Those which related to the 
chromatographic determination of phenethylamine alkaloids were reviewed by Pellati & 
Benvenuti (2007). In this review, however, they focused on the detection of citrus 
alkaloids that are present in dietary supplements rather than in common foods, drinks 
and plant material. These methods included GC and GC-mass spectrometry (GC-MS) 
(Cabezas et al., 2013; Marchei, Pichini, Pacifici, Pellegrini, & Zuccaro, 2006; Rossato 
et al., 2010); capillary electrophoresis (CE) (Avula, Upparapalli, & Khan, 2005; 
Chizzali, Nischang, & Ganzera, 2011; Liu, Cao, Zheng, & Chen, 2008; Luo, Tan, Xu, 
Yang, & Yang, 2008); thin layer chromatography (TLC) (Bagatela, Lopes, Cabral, 
Perazzo, & Ifa, 2015; Shawky, 2014); ion exchange liquid chromatography (Niemann & 
Gay, 2003; Tang et al., 2006; Thevis, Koch, Sigmund, Thomas, & Schanzer, 2012); and 
UPLC (Kim, Kwak, Ahn, & Park, 2014). The most common method for adrenergic 
amine analysis in CA was on RP-HPLC (Table 4) (Beyer, Peters, Kraemer, & Maurer, 
2007; Di Lorenzo et al., 2014; Viana et al., 2013; Viana et al., 2015; Wang & Zhao, 
2015).  Further background of these methods will be discussed in Chapter 4. However, 
the above mentioned approaches to adrenergic amine determination in CA-containing 
PWS involved extensive sample preparation, long run times and/or the use of non-
volatile mobile phases which were incompatible with mass spectral detection.    
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Table 4 Comparison of HPLC analytical methods for CA analysis 
 
Compound analysed 
Sample 
preparation Stationary phase Mobile phase Detection Accuracy 
Limits of Quantitation & 
Detection Author 
synephrine, octopamine, 
tyramine, N-
methyltyramine, hordenine 
 
Sonication with 
0.1% H3PO4 
Luna C18 column (150 mm 
x 3.0 mm, 5 µm) 
ACN/20mM borate buffer (pH 
8.8) (20:80, v/v), with 10mM 
sodium 1-hexane sulfonate UV, 224 nm 
97.7-104.0% (syn), 98.9-99.6% 
(oct), 95.9-117% (tyr), 90.7-
103% (nmt), 99.1-107% (hor) LOQ: 300 µg/g in raw plant material (Roman et al., 2007) 
synephrine, octopamine, 
tyramine, N-
methyltyramine, hordenine 
 
sonication with 
methanol/DMSO 
(1:1) 
Synergi Hydro-RP column 
(250 mm x 4.6 mm, 4 µm) 
0.1 Sodium acetate buffer (pH 
5.5)/ACN UV, 280 nm 98.0-103% 
LOD: 0.03 µg/mL (syn), 0.02 µg/mL 
(oct),0.02 µg/mL (tyr), 0.05 µg/mL 
(nmt), 0.05 µg/mL (hor) 
(Avula, Upparapalli, 
Navarrete, & Khan, 2005) 
synephrine, octopamine, 
tyramine 
 
sonication with 
0.1M HCl 
Spherigel C18 column (250 
mm x 4.6 mm, 4 µm) 
Aqueous solution of 32mM 1-
ethyl-3-methyllimidazolium 
tetrafluroborate [EMIM][BF4] UV, 273 nm 
95.3-101.3% (syn), 74.4-103.2% 
(oct), 80.0-101.5% (tyr) 
LOD: 0.2µg/mL (syn), 0.1 µg/mL 
(oct), 0.1 µg/mL (tyr), (Tang et al., 2006) 
synephrine, octopamine, 
tyramine, N-
methyltyramine, hordenine 
 
sonication with 
water 
pre-column 
derivatization(A): Luna C18 
column (250 mmx 4.6 mm, 
5 µm), Direct RPLC 
A: methanol/water (55:45, v/v) 
gradient. 
A:fluorescence 
detector   
λem = 455 nm ,   
λex = 340 nm. 
B:with 
A: 99.5-101.3%;RSD=0.8-1.2% . 
B:98.7-102.6%;RSD=1.1-2.3% 
LOD: A= 0.05-0.07 pmol, B= 0.21-
1.04 pmol. LOQ: A=0.17-0.23 pmol, 
B=0.7-3.47 pmol (Gatti & Lotti, 2011) 
synephrine, octopamine, 
tyramine, N-
methyltyramine, hordenine 
 magnetic stirring 
LiChrospher RP-18 column 
(250 mm x 4 mm, 5 µm) 
Aqeous SDS:SDS in ACN 
(62:38, v/v) UV, 224 nm. Average RSD values <15% 
LOD: 1.8-7.5 ng/mL LOQ:  
6.0-25 ng/mL (Di Lorenzo et al., 2014) 
synephrine 
sonication with 
ACN/water (80:20, 
v/v) 
Xterra RP18 column (150 
mm x 4.6 mm, 5 µm) 
Water (5 mM SDS)/ACN 
gradient UV, 210 nm 101.10% LOD: 0.01 µg/mL (Schaneberg & Khan, 2004) 
synephrine, octopamine, 
tyramine 
 
sonication with 
0.37% HCl 
HyperClone C18 BDS 1 
column (100 mm x 4.6,  
3 µm) 
water (3 mM SDS): 
ACN/methanol (3 mM SDS) 
gradient UV 210 nm 97.5-102.0% 
LOD: 0.23 µg/mL (syn),0.46µg/mL 
(oct), 0.23 µg/mL  (tyr). LOQ: 0.8 
µg/mL (syn), 0.62 µg/mL (oct), 0.8 
µg/mL (tyr) (Ganzera et al., 2005) 
Synephrine 
 
magnetic stirring 
with dilute mobile 
phase 
YMC phenyl column  
(250 mmx 3.0 mm, 5 µm) 
0.1M sodium acetate/acetic acid 
(pH 4.8) with triethylamine and 
2% CAN UV, 255 nm 85-102% 
 
(Hurlbut et al., 1998) 
Synephrine 
 
magnetic stirring 
with acidified 
acetone/water (4:1, 
v/v) 
Zorbax 300-SCX column 
(250 mm x 4.6 mm, 5 µm) 
0.4M Sodium phosphate buffer 
(pH 3.0/water/ACN (50:35:15, 
v/v/v) 
UV: 205,210 and 
225 nm 93.2-97.5% LOQ: 0.016 µg (Niemann & Gay, 2003) 
synephrine enantiomers 
 
sonication at 
ambient temperature 
LiChrospher RP-18 column 
(75mm x 4mm, 5µm) 
connected to  Sumichiral 
OA-5000 column (250 mm x 
4.6 mm, 5 µm) 
aqeous 1 mM copper (II) acetate 
and 20 mM ammonium acetate 
(pH 6.4)/ methanol (99:1, v/v) MS, 1.0V selectivity: 1.23 Resolution: 1.09 - 
(Kusu, Matsumoto, & 
Takamura, 1995) 
synephrine, octopamine, 
tyramine, N-
methyltyramine, hordenine 
 
PFE and sonication 
techniques 
Discovery HS F5 (200 mm x 
4.6 mm, 5 µm) 
water (10 mM SDS) (pH 2.5) / 
acetonitrile (72:28, v/v) UV, 220 nm - 
LOD: 4.2 ng (syn), 3.5 ng (oct),  
5.9 ng (tyr),5.5 ng (nmt) (Putzbach et al., 2007) 
positional isomers of 
synephrine 
 sonication in water 
Discovery HS F5 (150mm x 
4.6 mm, 5 µm) 
10 mM ammonium acetate in 
water: ammonium acetate in 
metanol (70:30, v/v) UV, 220 nm - 
LOD: 11 ng (p-synephrine), 10 ng 
(m-synephrine). LOQ: 33 (p-
synephrine), 30 (m-synephrine) (Santana et al., 2008) 
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For the analysis of charged, basic species such as synephrine, octopamine and tyramine 
(Table 5), with relatively high pKa’s ranging from 8.9 to 10.5, conditions must be in 
place to either neutralise them or introduce a modifier such as an ion pair reagent (IPR) 
in order to achieve good peak shape. Unlike dissociated acids, which, due to their 
negative charge, elute rapidly, protonated bases would often have long retention times 
and poor peak shape. This retention behaviour is due to the interaction of the positively 
charged amine with residual silanol groups on the silica surface of the stationary phase 
not coated with the non-polar adsorbed material. One method of suppressing silanol ion 
formation is to use IPR such as sodium dodecyl sulphate (SDS) which binds to the 
silanol groups resulting in improved peak shape and retention behaviour. A number of 
studies incorporated IPRs for the detection of Citrus amines (Ganzera, Lanser, & 
Stuppner, 2005; Penzak et al., 2001; Putzbach, Rimmer, Sharpless, & Sander, 2007; 
Roman, Betz, & Hildreth, 2007; Tang et al., 2006). Ganzera et al. reported a method for 
the simultaneous detection of alkaloids in CA and ES. The samples were extracted with 
0.37% hydrochloric acid via sonication. The column used was a HyperClone C18 BDS 1 
column (100 mm x 4.6 mm, 3 µm), with a gradient elution of mobile phase A, 3 mM 
aqueous SDS (pH 4.0); B, 0.1% phosphoric acid containing 3 mM SDS; C,  
acetonitrile/methanol (2:1, v/v) at a flow rate of 1 mL/min. The UV detection was at 
210 nm. The dietary supplements containing CA contained 0.08-3.05% of synephrine 
whilst octopamine and tyramine were found to be below the limits of detection (LOD).  
This method was sensitive but the use of the IPR hindered the use of mass detection. 
 
Table 5 Comparison of chemical properties of synephrine, octopamine and tyramine 
 
      
Compounds Synephrine Octopamine Tyramine 
Molecular Formula 𝐶9𝐻13𝑁𝑂2 𝐶8𝐻11𝑁𝑂2, 𝐶8𝐻11𝑁𝑂 , 
Molecular Mass 
(g/mol) 167.2 153.2 137.2 
pKa 9.3 8.9 10.5 
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Use of IPRs, however, is usually prohibitive with MS detectors since they lower the 
selectivity and decrease reproducibility. An alternative is to derivatise the sample used 
by Gatti et al. (2012) for the analysis of primary phenethylamines in supplements using 
pre-column derivatization with fluorescence detection and in contrast to direct RP-LC 
with fluorescence detection. The chromatographic separation after pre-derivatization 
with O-phthadialdehyde (OPA) was performed with a Phenomenex Luna 5 µm C18 
column (250 mm x 4.6 mm) using methanol and sodium acetate buffer (pH 5.5) by 
gradient elution fluorescence detection, the total run time was 55 minutes. The study 
concluded that the derivatization method yielded recovery ranging from 99.5-101.3% 
with RSD ranging from 0.8 to 1.2% (Gatti et al., 2012; Liu et al., 2009). However, 
derivatization protocols are time consuming, subject to introduced additional impurities 
and/or cause ion-suppression for mass detection (Qi et al., 2014). However, these 
methods also used IPRs for amine retention. HPLC-quadrupole MS is a selective and 
sensitive method, but is more suited to quantify known compounds that are available as 
pure reference standards. HPLC coupled to triple quadrupole tandem MS (MS/MS) or 
HPLC coupled to an ion trap MS (MS
n
) is a better set up for unknown compounds. 
HPLC-MS/MS has been applied to the detection of ephedrine alkaloids and synephrine 
in dietary supplements (Gay, Niemann, & Musser, 2006; Putzbach et al., 2007; Santana, 
Sharpless, & Nelson, 2008). 
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1.4.2 HPLC Analysis of Caffeine & Derivatives 
 
Several analytical methods have been used for the analysis and quantification of 
caffeine and DMX. These methods include gas chromatography (GC), gas 
chromatography-mass spectrometry (GC-MS) (Shrivas & Wu, 2007), capillary 
electrophoresis (CE) (Chen, et al., 2010; Meinhart et al., 2010; Uysal et al., 2009), thin 
layer chromatography (TLC) (Aranda & Morlock, 2007; Ford et al., 2005), and UPLC 
(Vaclaviket al., 2014; Venhuis et al., 2014; Zacharis et al., 2013). Based on a recent 
review (Monteiro et al., 2016), RP-HPLC is the most common analytical method used 
for caffeine and DMX analysis. Table 6 shows a small representation of the current 
methods available for caffeine analysis in supplements and biological fluids. 
Most methods of DMX separation in biological fluids and foods do not separate PX and 
TP (Bispo et al., 2002; Hasegawa et al., 2009; Kanazawa et al., 2000; Martinez-Lopez et 
al., 2014; Thomas et al.,2004). It has been noted that the three DMX isomers are 
difficult to separate in RP-HPLC (Randon et al., 2010). The three DMX are 
configurational isomers, have identical masses and are challenging to differentiate 
analytically without derivatization. Further developments for a HPLC/UV-MS method 
used in our studies will be discussed in chapter 4. 
Table 6 Comparison of methods for caffeine analysis 
 
 
 
 
 
 
 
 
 
 
 
Compound 
analysed  
Sample 
preparation 
Stationary phase Mobile phase Detection Accuracy Author 
Caffeine, TB, 
TP 
 
Filtered using filter 
paper and Soxhlet 
extraction Bondesil C18 
methanol-water-
acetiic acid UV 273 nm N/A (Bispo et al., 2002) 
Caffeine, TB, 
TP 
 
Dissolve in water 
and filtered with 
filter paper 
Li-Chrospher 100 
RP-18 (244 mm x 
4.4 i.d., 5 µm) 
water, ethanol, ecitic 
acid UV 273 nm 94% to 106% 
(de Aragao, Veloso, Bispo, 
Ferreira, & de Andrade, 
2005) 
Caffeine, TB, 
TP 
 N/A 
UPLC C18 BEH 
(50 mm × 2.1 mm, 
1.7 μm) 
0.1 vol% formic 
acid/CH3OH 
(92.5:7.5, v/v) UV 272 nm 90% and 108% (Zacharis et al., 2013) 
Caffeine, 
Taurine 
 
extracted with 4 
mL of 
hexane/isopropanol 
Phenomenex Luna 
C18 (150 mm × 
4.6 mm, 3 μm) 
water/methanol/acetic 
acid (75:20:5, v/v/v) 
Mass 
spectrometry 70.1 and 94.4% 
(Marchei, Pellegrini, Pacifici, 
Palmi, & Pichini, 2005) 
Caffeine, TB, 
TP 
vortexed and 
centrifuged (10 
mins, 10,500 rpm) 
Kinetex C18 (4.6 
× 250 mm, 5 μm) 
water/ methanol 
+0.1% formic acid UV 272 nm 95 and 104.5% (Martinez-Lopez et al., 2014) 
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1.5 Research Questions 
 
1. Do CA-containing PWS comply with the 30 mg per dose limit of synephrine set by 
the TGA of Australia? 
2. Is there a discrepancy in synephrine concentrations between overseas sourced and 
locally manufactured PWS?  
3. Are the levels of caffeine measured in a range of CA-containing PWS products, 
consistent with that listed on their labels? 
1.6 Hypotheses 
 
1. It is hypothesised that pre-workout supplements containing CA as a labelled 
ingredient contain levels of synephrine higher than the 30 mg/dose limit set by the 
TGA, 
2. It is hypothesized that pre-workout supplements sourced from overseas will have 
higher amounts of synephrine compared to locally available PWS. 
3. It is hypothesized that levels of caffeine in pre-workout supplements labelled to 
contain CA are higher than that listed on their labels. 
1.7 Aims 
 
The primary aim of this thesis was to quantitatively determine the amounts of 
synephrine, octopamine, and tyramine in range of CA-containing PWS by HPLC with 
UV-MS detection. A secondary aim was to determine the amounts of caffeine and 
DMX present in PWS with HPLC-UV/MS. 
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2.1 General Principles of Chromatography 
 
Successful chromatography requires that parameters which affect the passage of 
molecules through a column be measured, known as elution.  The distribution of 
analytes in chromatography can be expressed in terms of the equilibrium of the analyte 
between two phases whereby: 
[𝐴]𝑚𝑜𝑏𝑖𝑙𝑒 ↔  [𝐴]𝑠𝑡𝑎𝑡𝑖𝑜𝑛𝑎𝑟𝑦 
Where the equilibrium constant, Keq can be expressed as 
𝐾𝑒𝑞 =  
[𝐴]𝑠𝑡𝑎𝑡𝑖𝑜𝑛𝑎𝑟𝑦
[𝐴]𝑚𝑜𝑏𝑖𝑙𝑒
 
Such that, at low concentrations of A, the concentration of A in the mobile phase is 
directly proportional to that in the stationary phase. These quantities, however, are 
difficult to measure. (Note overloading the column leads to a disproportionate amount 
of A in one phase and decreased column efficiency). Alternatively the capacity factor, 
K
’
eq
 
(the ratio of the moles of A in each phase) provides a means of incorporating 
volume and also time into an equation developed for determining the amount of time an 
analyte spends in the stationary phase or retention factor, k (see below). These 
quantities, including void volume/time and retention volume/time are more easily 
determined from the chromatography. A full mathematical derivation was expanded by 
Mikes (2011). 
The key goal in most chromatographic analysis is obtaining optimum resolution of each 
analyte of interest to facilitate accurate quantification. Achieving this requires 
understanding of the factors that influence resolution. Resolution (R) can be represented 
by the following equation which relates resolution to other key metrics in 
chromatography such as efficiency (N), selectivity () and retention factor (k)  
(Heftmann, 2004).  Several equations for resolution in LC have been described, varying 
in their degree of complexity and discussed here. A simplified equation is presented in 
Equation 1 which assumes that the value of k (and ) for both analytes are similar: 
𝑅 =   
√𝑁
4
. (𝑎 − 1).
𝑘1
1+ 𝑘𝑎𝑣𝑔
    
 
(Equation 1) 
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The k and α of the column are influenced by pH and in the strength of the mobile phase. 
Efficiency and resolution depend on the variations of column size, packing material and 
internal dimensions and flow rate. k1 is the retention factor of the first product and kavg is 
the average retention factor of the first product multiple sample set.  
The retention factor (k) is a unitless measure of a compound’s retention on a 
chromatographic system such that: 
  𝑘 =
𝑉𝑅−𝑉0
𝑉0
=
𝑡𝑅−𝑡0
𝑡0
    (Equation 1.1) 
where 𝑉𝑅 is the anaylte’s retention volume, 𝑉0 is the volume of the mobile phase in the 
chromatographic system. 𝑡𝑅 represents the  retention time of the analyte, and 𝑡0 is the 
elution time of an unretained component, known as the column dead time. (𝑡0 can also 
be described as 𝑡𝑀 (according to International Union of Pure and Applied Chemistry, 
IUPAC, terminology). Changes in 𝑘 result in the largest effect on resolution since R is 
proportional to k (R ∝ k/ (1-k), see Eq. 1). 
 
 
 
Figure 7 Diagrammatic representation of a chromatogram depicting the relationship between retention time (tR) 
and the column dead time (to). 
 
 
  
 
Dead Point 
Dead 
Volume, 
Vo 
Dead 
Time, 
 to 
Retention Time, tR 
Corrected Retention Time, t’R 
Retention volume ,VR 
Corrected Retention volume ,V’r 
Peak width at ½ Height 
Peak width at Base 
   
39 
Unreliable chromatography ensues with retention factors of less than 1 since analytes 
are unlikely to be retained. Conversely, k values over 10 means longer run times and 
lower peak heights. Thus an optimum value for k is around 5, although k values within 
the range of between 1 to 10 are satisfactory. k can easily be determined from the tR of 
each analyte knowing the dead time of the system. One of the easiest ways to modify 
the retention factor is to alter the mobile composition by increasing the organic 
component. This coaxes the hydrophobic component of the analyte back into the mobile 
phase from the stationary phase thereby eluting earlier. Since k is not influenced by 
small changes in flow rate nor column dimensions, this is often one of the first 
parameters to optimise and useful for modifying a method developed on a different 
system (Dorsey, Cooper, Wheeler, Barth, & Foley, 1994).  
Selectivity (α) is the ability of the chromatographic system to discriminate between two 
different analytes. It is defined as the ratio of corresponding retention factors, expressed 
as: 
   𝛼 =  
𝑘1
𝑘2
    (Equation 1.2) 
Where k2 and k1 are the retention factors of two analytes. 
At a value of 1 the two analytes are co-eluting thus, by definition, selectivity values are 
always greater than 1 and should be as high as possible. The higher the value the greater 
the distance between the apices of the two peaks.  
Selectivity is a factor of the chemistry of analyte, mobile and stationary phases, so 
modifications in all these factors can be performed to optimise selectivity. For example, 
changing the organic solvent from methanol to acetonitrile, changing the pH of the 
mobile phase, changing the column chemistry or altering the column temperature.  
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Efficiency is a measure of the degree of peak broadening produced by a particular 
column. Peak broadening is caused by dispersion forces on the analytes as they 
transverse the system resulting in their typical Gaussian shape. It can be expressed 
mathematically as in Equation 1.3: 
𝑁 = 16 (
𝑡𝑅
𝑤
)
2
 or 𝑁 =  5.55 (
 (𝑡𝑅)
2
(𝑤1
2⁄
)
2) (Equation 1.3)  
where 𝑡𝑅 is the retention time, w  is the peak width of the baseline, 𝑤1
2⁄
 is the width of 
peak at half height of peak.  
Efficiency is expressed as the number of theoretical plates (N) (Heftmann, 2004). 
Theoretical plates was a concept originating from fractional distillation and applied to 
chromatography. It was a concept whereby the entire column can be thought of as 
consisting of discrete sections, whereby the analytes can equilibrate. In lay terms, the 
higher the number of plates, the greater the equilibration and the narrower peak shape. N 
depends on column dimensions, but for a typical column of 4.6µm diameter of 100 mm 
length acceptable values of N would be between 5000 - 8000. N is inversely 
proportional to the space between the plates or plate height. Note that the latter is often 
referred to as the Height Equivalent or Theoretical Plate or HETP (Dorsey et al., 1994). 
Values of efficiency are often given for quoting the efficiency of a particular column. 
Predetermined values may be in place in a quality control setting such that when the 
column efficiency passes below a set value, the column use is terminated.  
Band broadening is a phenomenon that decreases the efficiency of the separation, which 
results in poor peak resolution and overall chromatographic performance. The Van 
Deemter equation was described to understand the main factors that result in a loss of 
column efficiency. The equation relates the HETP of the column to the various kinetic 
parameters during mobile phase flow. It was described as the following: 
𝐻𝐸𝑇𝑃 = 𝐴 +
𝐵
𝑢
+ 𝐶𝑢   (Equation 2) 
Where A is the Eddy-diffusion parameter, B is the diffusion coefficient of eluting 
particles, C is the mass transfer coefficient of the analyte between mobile and stationary 
phase, and u is the linear velocity of the mobile phase.  
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Eddy diffusion describes the variations in mobile phase flow or analyte flow path within 
the column. The variations in an analyte flow ‘path’ are caused by the lack of 
homogeneity in the column packing material and particle size. A well-packed column 
with smaller stationary particle size is ideal to minimise Eddy Diffusion. 
The diffusion coefficient can determine the extent of band broadening resulting from 
analyte molecules contained in the injection solvent dispersing within the tubing of the 
HPLC. The amount of analyte dispersion is influenced by the length and internal 
diameter of the tubing as well as the internal volume of the detector flow cell. 
Increasing the flow rate of the method will reduce the effect of the diffusion coefficient.  
Mass transfer occurs due to stagnation of mobile phase within the porous surfaces of the 
packing material of the stationary phase. Band broadening also occurs when the analyte 
molecules adsorb to the pores of the stationary phase at varying rates. These effects may 
be reduced by decreasing the size of the packing material and lowering the flow of the 
mobile phase 
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2.2 Developing a Systematic Work Flow 
 
Chromatographic method development can often be time-consuming and difficult 
whereby the typical approach is to select a combination of solvents, pH, buffer and 
column as a starting point, making adjustment to the composition until a suitable 
method is selected. The systematic workflow outlined in Figure 8 below, was used to 
develop the methods set out in Chapters 3 and 4.  
 
Figure 8 Diagram of method development workflow 
Factors such column chemistry, strength of organic solvents, temperature and pH were 
evaluated to determine the most effective experimental parameters to achieve 
resolution. The best conditions producing optimum values for these parameters were 
used to refine the chromatography.  
Finally, a single-laboratory validation was conducted. The following method section 
describes experimental procedures which apply equally to both analytical experiments, 
such as solid phase extraction of samples (sample clean-up). In cases where specific 
methodology applicable to one or the other experiments apply, these more specific 
protocols may be found within their respective chapters, for example, Chapter 3 - HPLC 
detection of amphetamine-like compounds and Chapter 4 - HPLC detection of caffeine.  
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2.2.1 Sample Preparation 
 
 An essential aspect for obtaining good chromatography is to ensure the sample injected 
into the HPLC system is free from unwanted contaminants that may interfere with the 
chromatography. The challenge of sample preparation for PWS is the complexity of its 
matrix. Most PWS contain a mixture of ingredients in a ‘proprietary blend’. A problem 
with proprietary blends is that the FDA does not monitor the PWS labels to guarantee 
specific amounts of ingredients are present. Common ingredients generally found in 
PWS are caffeine, creatine, arginine, taurine, β-Alanine, and phosphate (Eudy et al., 
2013). In addition, other non-active ingredients include colouring, flavourings and bulk 
powders with a wide range of physicochemical properties. Figure 9 shows an example 
of a typical label of a PWS supplement containing CA. Two sample preparation 
techniques were explored based on their conventional use and straight forward 
approach. 
 
Figure 9 Example of a typical PWS supplement label 
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2.2.1.1 Liquid- Liquid Extraction (LLE) 
 
LLE was first trialled, during the early stages of project method development, as it was 
a relatively cheap and simple technique (Figure 10)  
  
 
 
Figure 10 Diagrammatic representation of the LLE method used 
Powdered PWS sample (1 g) was dissolved in a total of 10 mL of MilliQ water and 5M 
sodium hydroxide (NaOH), where the pH was adjusted to 12. This ensured the trace 
amines were in a neutral state. The mixture was sonicated for 30 minutes to completely 
dissolve the components. The solution was then placed into a separating funnel. Ethyl 
acetate (10 mL) was used to extract the amines. The aqueous layer was discarded and 
the remaining organic phase was kept. Then, 1 mL of 1M hydrochloric acid and 9mL of 
water was added to the solution to protonate the retained amines. Upon separation of 
solvent layers, the organic layer was discarded and the aqueous layer was evaporated to 
dryness at room temperature (24°C). The dried residue was then reconstituted with 1.5 
mL methanol and aliquoted for HPLC analysis.  
The LLE method was subject to poor repeatability and reproducibility and this, coupled 
with long sample preparation time, limitations to the selectivity and difficulties with 
emulsions, made a rapid analysis of PWS difficult. For this reason, it was decided to 
turn to a much more consistent and robust method of sample preparation such as solid 
phase extraction. 
 
Add H
2
O 
(10mL)  
sonicate 
20mins 
Adjust pH to 
~11 
Add EtOAc 
(10mL) 
Or 1 
capsule 
1g 
Collect aq. 
phase 
Discard 
aq. 
phase 
Add H
2
O 
(10mL) 
Adjust pH 
to ~5 
Discard 
organic phase 
Step 1: Remove aqueous impurities 
Step 2: Remove organic impurities 
Collect 
organic 
phase 
Evaporate to dryness, 
Reconstitute in MeOH 
(1.5 mL) 
   
45 
2.2.1.2 Solid Phase Extraction (SPE) 
 
The Oasis PRIME HLB (3 mL, 60 mg cartridge, Waters, Ireland) cartridges were 
selected because they were especially suitable for basic compound analysis such as the 
amphetamine like compounds of interest in CA-containing supplements. These 
cartridges were also suitable for the extraction of xanthines. The workflow is set out in 
Figure 11.  
 
 
Figure 11 Representative diagram of the SPE procedure with the Oasis HLB cartridge 
CA-containing PWS (1 g) was weighed and 10 mL of MilliQ water was added. The 
mixture was sonicated under ambient temperature for 30 minutes. MilliQ water was 
used to wash polar impurities away whilst an acetonitrile: methanol mixture (90:10, v/v) 
was used to elute the non-polar components within PWS into 2 mL HPLC vial. Samples 
were evaporated to dryness prior to reconstitution in mobile phase and stored at 4°C 
before subsequent HPLC analysis. Each supplement sample was prepared in triplicate. 
This method of sample clean-up was found to have a high degree of specificity with the 
SPE sorbent, producing a more consistent yield, and using less solvent per sample 
compared to LLE.  
 
 
 
 
 1 gram PWS 
Add H
2
O (10mL)  
sonicate 30 mins 
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2.2.2 Stationary Phase Selection 
 
The column selection was made based on the specific analyte being considered. For 
example, columns best able to retain charged amines, such as the amphetamine-like 
compounds, must be stable at high pH and able to maximise aromatic interactions 
between the analyte and the stationary phase particle coating. During method 
development, access to a wide range of columns can be a limiting factor with budget 
constraints. In these cases, developing skills in optimising the parameters such as those 
discussed in section 2.1 is essential.  
The choices of columns available for this study was narrowed down to a Xselect CSH 
phenyl-hexyl (3.5 µm, 4.6 x 100 mm, i.d., Waters, Ireland), Xselect HSS T3 (5 µm, 3.0 
x 150 mm, i.d., Waters, Ireland) and Xbridge BEH C18 (2.5 µm, 3.0 x 100 mm, i.d., 
Waters, Ireland). 
 
Table 7 Comparison of column chemistry and dimensions 
Ligand and 
Particle Type 
 
CSH Phenyl- Hexyl 
 
BEH C18 
 
HSS T3 
Particle Size 
(µm) 
3.5 2.5 5.0 
pH range 1-11 1-12 2-8 
Temperature 
limit (°C) 
45- 60 45-80 45 
Description General purpose 
alternative selectivity 
ligand that provides π-
π interactions with 
polyaromatic 
compounds, increased 
loading capacity for 
basic compound 
General purpose column ideally 
suited for method development due 
to extreme pH stability and 
applicability to the broadest range of 
compound classes. 
Aqueous mobile-phase compatible column 
designed for exceptional polar compound 
retention. 
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The column packing materials listed in Table 7 for each column consisted of a Charged 
Surface Hybrid (CSH), Ethylene Bridged Hybrid (BEH), and High Strength Silica 
(HSS) proprietary to Waters (Waters, 2016). The HSS and BEH columns chemistry 
were C18 although with different pH and temperature resistances due to their respective 
end-capping. However, the phenyl-hexyl chemistry of the CSH column has advantages 
in aromatic compounds retention such as an increased π-π interaction ( Gibson & 
Fowler, 2014). Further specific developments of the column chromatography will be 
discussed in Chapter 3 and 4. 
2.2.3 Mobile Phase Selection 
 
The organic mobile phases trialled during method development, acetonitrile and 
methanol, are commonly used in LC. Acetonitrile is a stronger solvent compared to 
methanol and this fact can be exploited during the optimisation process.  Both solvents 
have low absorbance at typical analysis wavelengths for UV detection with acetonitrile 
having a UV cut-off wavelength of 200 nm while that for methanol is 240 nm. An 
increase in the organic content of the mobile phase of 10% will decrease the retention 
factor, k, for each analyte by a factor of 2 to 3.  In addition, organic modifiers have 
different viscosities. A less viscous mobile phase is desirable as it reduces the 
backpressure of the chromatographic system. Further discussions on the impact of 
mobile phase selection will be detailed in their respective results section (Chapter 3 & 
4). 
 
2.2.4 pH Modifiers in Mobile Phase  
 
As mentioned, many RP-HPLC experiments are maintained at low pH (around 2-3) to 
minimise silanol ionisation. Unfortunately, at such low pH values, amphetamine-like 
compounds (pKa > 9), would be positively charged and interact with the negatively 
charged silanol groups on the stationary phase increasing retention and causing peak 
tailing. Acidic modifiers such as trifluroacetic acid (TFA) and formic acid (FA) were 
used to decrease the pH of the mobile phases reducing charged silanol group 
interactions. However, the acidity of TFA is greater than formic acid. The impact of 
acid as a pH modifier will be explored further in Chapter  4.  
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Retention of basic analytes is still possible using a method such as ion-pair reagents 
which overcomes these unwanted silanol interactions. It was important to identify pH 
modifiers that would overcome these interactions while being compatible with QDa 
mass detection. As a result, ammonium hydroxide was selected for the separation of our 
amphetamine-like compounds discussed in Chapter 3.  
2.2.5 Apparatus and Materials 
 
All experiments were carried out using an Alliance e2695 (Waters, Ireland) separations 
module with a quaternary solvent system, equipped with auto-sampler, 100 µL injection 
loop, column oven, model 2489 UV/Vis Detector (Waters, Ireland) in series with an 
Acquity quadrupole diode array (QDa) mass detector (Figure 12). Empower V3 
software was used for data acquisition and processing. Samples were filtered through a 
0.45-micron filter prior to solid phase extraction (Oasis PRIME HLB, 3 mL, 60 mg 
cartridge, Waters, Ireland). Synephrine, octopamine, tyramine, phenylephrine, caffeine, 
TP, TB, PX and etofylline were obtained from Sigma-Aldrich (Sydney, Australia). 
HPLC grade Optima methanol, Optima acetonitrile and Optima grade formic acid were 
from Fisher Scientific (Geel, Belgium). HPLC grade water from a Milli-Q system 
(Millipore, Bedford, MA, USA) was used. All chemicals were of analytical grade 
suitable for LC-MS. 
 
Figure 12 Representative Alliance e2695 set up paired to a UV/Vis detector and a QDa detector 
 
 
 
   
49 
2.3 Method Validation  
 
The validation process aims to demonstrate that the analytical method being developed 
is fit for purpose. In a quality assurance setting, there are specific regulatory 
requirements that must be demonstrated for a method to be considered valid (ICH 
Expert Working Group, 1994). A complete method validation involves inter-laboratory 
testing with more than one laboratory. However, access to other laboratories is often not 
possible and certainly beyond the scope of this study. Validation involves a 
demonstration of reliable results and an acceptable degree of repeatability. The 
validation parameters are set by the International Conference On Harmonisation Of 
Technical Requirements For Registration Of Pharmaceuticals For Human Use (ICH 
Expert Working Group, 1994) was the chosen guideline for this study. 
The validation parameters determined were as follows: 
2.3.1 Selectivity 
 
Selectivity is the ability to distinguish between the analyte being measured and other 
substances present. Selectivity was confirmed by the use of UV-detection and QDa-MS 
by incorporating a starting condition blank as well as a dietary supplement blank (not 
containing any of the analytes being measured). 
2.3.2 Precision 
 
Intra-day and inter-day assay precision, reported as relative standard deviation (RSD %) 
of standard peak areas and were calculated based on the equation:  
RSD % = Standard deviation/ mean x 100 
Intra-assay precision was determined by analysing three different concentrations (5, 50, 
and 100 µg/mL) of the internal standard (IS) from each method in triplicate on the same 
day. Inter-day precision was determined based on analysing these concentrations over 
three separate days. 
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2.3.3 Accuracy 
 
Accuracy was determined by evaluating spiked PWS with 3 concentrations of standards 
calculating RSD % between the mean values.  
2.3.4 Linearity 
 
For each run, 6 standard concentrations were prepared and analysed with three 
independent injections. Concentrations ranged between 5 µg/mL – 100 µg/mL. Linear 
regressions were generated on 3 separate days using the standards to IS peak area ratios 
by weighted (1/x
2
) least-squares linear regression. Calibration curve equation and 
correlation coefficients (r
2
) were calculated. The acceptance criteria for acceptable 
calibration curve were r
2
 of 0.99 or better. 
 
2.3.5 Limit of Detection and Limit of Quantification 
 
Determination of the limits of detection (LOD), limits of quantitation (LOQ), intra-
assay and inter-assay precision were performed according to outlined in the 
International Conference on Harmonization of Technical Requirements for Registration 
of Pharmaceuticals for Human Use (ICH Q2 (R1), 2005). The calibration curves were 
obtained by plotting the area of base peak of extracted chromatogram against the 
internal standard. Limits of detection (LOD) and limits of quantitation (LOQ) were 
determined based on their respective signal-to-noise ratio (S/N) where the desired S/N 
for the LOD is between 3 or 2:1, whereas the desired S/N for the LOQ is 10:1. 
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2.3.6 S/N Determination Within the Empower 3 Software. 
 
In 2009, the United States Pharmacopeia (USP) defined Signal-to-Noise (S/N) as: 
    𝑆 𝑁⁄ =
2ℎ
ℎ𝑛
        (Equation 3) 
 
Where h is the height of the peak corresponding to the component and hn is the 
difference between the largest and smallest noise values observed over a distance equal 
to at least 5 times the width at half-height of the peak. This approach does not 
compensate for local systematic drift. Basically, if the noise within this system 
increases, the S/N decreases which could result in larger LOD and LOQ values. 
Therefore, it is important to use the most representative noise value possible. To reduce 
the effects of drift, peak-to-peak noise calculation was done on the Empower 3 
software. The peak-peak noise determines the best-fit line regression line to the noise 
and calculates the residual amount for each data point.  
Peak-to-Peak noise was determined by the inclusion of a custom field (see below) in the 
‘Noise and Drift’ tab of the processing method. A noise interval of 60 points ensures it 
is at least a minimum of five times the width at half height of the peak of interest 
(Figure 13). The noise was determined in a peak-free region of the chromatogram to 
abide to the USP S/N time range. 
 
Figure 13 Empower 3 software window of noise and drift calculation 
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To determine the appropriate S/N within the method, a custom field was defined to 
determine the USP Signal-to-Noise. The custom field formula was: 
𝑆
𝑁
= 2 ∗ 𝐻𝑒𝑖𝑔ℎ𝑡 ∗
𝑆𝑐𝑎𝑙𝑒 𝑡𝑜 µ𝑉
𝑃𝑒𝑎𝑘 𝑡𝑜 𝑝𝑒𝑎𝑘 𝑛𝑜𝑖𝑠𝑒
 
Figure 14 shows this formula and the appropriate custom field parameters in the 
Empower 3 Edit Custom Field window. The S/N was calculated for each individual 
analyte peak found with each subsequent analysis. 
 
Figure 14 Empower 3 software of custom field window 
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2.3.7 The Theory of Internal Standard Use  
 
An internal standard (IS) is a known amount of a compound (different from the analyte) 
that is added to the unknown sample. The signal of the analyte is compared with signals 
from the IS to find out how much analyte is present. An ideal IS should be chemically 
similar to the analytes of interest, yet should have a chromatographic peak well 
separated from the analytes. This is so that uncontrolled matrix effects such as a change 
in analyte signal might have a similar effect on the IS.  
To use an IS, we prepared a known mixture of standard and IS to measure the relative 
response of the two compounds. The area (A) under each peak is proportional to the 
concentration (C) of the compounds injected. However, the detector generally has a 
different intensity to each component of the same injected concentrations of the analyte 
(x) and the IS.  The magnitude of difference of area found is known as the response 
factor (F). This is shown in equation 2.  
    
𝐴𝑥
𝐶𝑥
= 𝐹 .  
𝐴𝐼𝑆
𝐶𝐼𝑆
     Equation 3 
 
The equations above use a single mixture to find the response factor. To reduce the 
effects of experimental error, a multipoint calibration curve is preferred. Equation 3 is 
rearranged so that the variables of the equation can be plotted on a graph, where the 
gradient of the graph will be the response factor (Equation 3.1). 
    
𝐴𝑥
𝐴𝐼𝑆
= 𝐹 .  
𝐶𝑥
𝐶𝐼𝑆
   Equation 3.1 
 
Further application of the internal standard method will be discussed in Chapter 3, 
where phenylephrine is used as an internal standard to the method.  
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3.1 Background 
 
Concomitant with the increased popularity of CA-containing PWS in the community is 
the need for assessing the safety and efficacy of the components therein, especially in 
light of reports of their adverse effects. PWS are, by nature, complex matrices which 
require a selective and sensitive means of quantifying the active constituents.  A review 
of techniques for the separation, subsequent detection and finally quantification of the 
amphetamine-like compounds in PWS has already been discussed in Chapter 1.  
The most common method for separation of the adrenergic amines in CA was found to 
be RP-HPLC paired to a UV detector (Beyer et al., 2007; Di Lorenzo et al., 2014; Viana 
et al., 2013; Viana et al., 2015; X. L. Wang & Zhao, 2015). HPLC stationary phases are 
made of C18 bounded to silica, where the basic amines could interact with the silanol 
ions, resulting in poor peak shape and retention (Neue et al., 2004).  HPLC methods of 
CA amine separation with ion-pair reagents were used to improve retention of charged 
amines and improve peak shape (Di Lorenzo et al., 2014; Ganzera et al., 2005; Penzak 
et al., 2001; Putzbach et al., 2007; Roman et al., 2007). 
Di Lorenzo et al., developed a method to measure the amount of active amines in 
dietary supplements containing CA. HPLC analysis was carried out with a LiChrospher 
RP-18 column (250 mm x 4 mm, 5 µm), with a 30 minute gradient elution at 1 mL/min 
with mobile phases: A, 2.9 g/L sodium dodecyl sulphate (SDS) in water at pH 4.2; B, 
2.9 g/L SDS: ACN (62:38, v/v). UV detection was set at 224 nm.  The analytical 
recovery of the amines ranged from 85.9% to 108.4% and the LOD: 1.8-7.5 ng/mL 
LOQ: 6.0-25 ng/mL. The use of the SDS IPR prevented the potential use of MS. 
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Santana et al. (2008) developed two LC methods for the baseline separation and 
quantitative determination of p-synephrine and m-synephrine. The incorporation of MS 
assisted in confirming the identity of the resolved isomers. The chromatography 
involved a Supelco Discovery HS-F5 (pentaflurophenyl) column (150 mm x 4.6 mm, 5 
µm); mobile phase A= 10 mmol/L ammonium acetate in water; B= ammonium acetate 
in methanol; A/B= 70/30; at a flow rate of 1 mL/min. UV detection was set at 220 nm. 
The method resulted in a linear range of 0.001-11.318 µg of p-synephrine with LOD of 
11 ng. The tandem MS set up had gradient conditions as above but with a flow rate of 
0.5 mL/min with the detection and quantification was carried out with the use of ESI-
MRM/MS/MS. The linear range for this set up was 0.005- 10 ng with an LOD of 0.005 
ng. The results showed that m-synephrine was not detected in any of the tested dietary 
supplements. The study concluded that the LC/UV method was a more convenient 
method to use as a general screening method, while the LC/MS/MS method was more 
suited to a confirmatory method for verifying the presence of particular synephrine 
structural isomers in dietary supplements. 
The aforementioned approaches to adrenergic amine determination in CA-containing 
PWS either involved extensive sample preparation, long run times and/or the use of 
non-volatile mobile phases. Concern for the increasing consumption of stimulant-
containing dietary supplements in the general population (Eichner & Tygart, 2016) 
drives the need of an analytical method that is rapid, sensitive and cost effective.  
The aim of this study was to develop a rapid, accurate and simple HPLC-UV/MS 
method for the determination and quantification of the synephrine, octopamine and 
tyramine in CA-containing PWS.  
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3.2 Experimental 
3.2.1 Chemicals and Reagents  
 
The chemicals and reagents used in this chapter are detailed in General Methods 
(Chapter 2). The five PWS selected were MusclePrime (AllMax Nutrition) (A); Gold 
Standard Preworkout (OptimumNutrition) (B); 360Rage (360°Cut Performance 
Supplements) (C); ErgoBlast (ErgoGenix) (D) and PumpHD (BPISports) (E). The 
matrix blank was a PWS without CA, Beast Mode (Beast Sport’s Nutrition). The PWS 
samples A, C and D were purchased online (manufactured in the USA) while samples B 
and E were sourced from a local health store in South-East Queensland, Australia 
3.2.2 Standard and Sample Preparation  
 
Stock solutions (1 mg/mL) were prepared for all standards as well as internal standard 
(IS) and stored at 4°C until analysis. Phenylephrine (m-synephrine) was selected as IS 
since it is a positional isomer of synephrine and not naturally found in CA extracts 
(Pellati & Benvenuti, 2007). A linear dilution was prepared for each standard between 5 
µg/mL to 100 µg/mL for all standards. The results of concentrations outside this linear 
range will be discussed in section 3.4.1. The PWS samples were prepared using the SPE 
method detailed in Chapter 2.  
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3.3 Method Development 
 
According to the method development process depicted in Figure 8 (Chapter 2), by 
changing various parameters such as different column chemistries, mobile phase 
composition, temperature and gradient combinations, an optimised method for 
quantifying the adrenergic stimulants in PWS was achieved. The details of this process 
are outlined in the following sections to attain the best conditions for separation. 
3.3.1 Effect of Column Chemistry 
 
Two chromatographic columns were compared; an Xbridge C18 (2.5 µm, 3.0 mm x 100 
mm, i.d., Waters, Ireland) and an Xselect CSH phenyl-hexyl (3.5µm, 4.6 mm x 100mm, 
i.d., Waters, Ireland). These were selected based on their ability to interact with 
aromatic amines.  
To compare the effect on analyte retention of the two columns a series of 100 µg/mL 
standard mix (including IS) injections were run using an initial mobile phase gradient 
A: H2O + 0.1% NH4OH: 95 – 0% and B: ACN + 0.1% NH4OH: 5 – 100% over a period 
of 20 minutes with a flow rate of 1 mL/min at 30°C.  
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Figure 15 Comparison of column chemistry: (A) Xselect CSH phenylhexyl (3.5 µm, 4.6 x 100 mm, i.d.) and (B) 
Xbridge C18 (2.5 µm, 3.0 x 100 mm, i.d.). The standard compounds are represented by: (a) Octopamine; (b) 
Synephrine; (c) Tyramine; (d) Phenylephrine 
 
a 
b 
c 
a 
b 
c 
d 
Phenyl-Hexyl (4.6x 100mm, 3.5 µm) 
BEH C18 (3.0x 100mm, 2.5 µm) 
d *Phenylephrine (d)  
co-eluted with synephrine (b) 
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The elution order of the amines from the two columns was octopamine, followed by 
synephrine, phenylephrine and finally tyramine (Figure 15). This was as expected from 
their clogP values. The results are summarised in Table 8.    
 
Table 8 Summary of effects of column chemistry on CA amines 
Compound RT on Phenyl-hexyl column 
(mins) 
RT on C18 column 
(mins) 
Octopamine 3.79 1.88 
Synephrine 5.61 3.63 
Phenylephrine Not detected* 5.74 
Tyramine 7.55 6.06 
*May have co-eluted with synephrine 
The phenyl functional group of the phenyl-hexyl column introduce the potential for 
additional molecular interactions such as π-π interactions (Yang, Fazio, Munch, & 
Drumm, 2005). These effects most likely explain the increased RT for the analytes on 
the phenyl-hexyl column.  
It was noted that the peaks observed on the phenyl-hexyl chromatogram were broader 
than those seen on the C18 chromatogram. Peak broadening can occur due to factors 
such as eddy diffusion, longitudinal diffusion and mass transfer, as mentioned in the 
previous chapter. Since the length of the column and instrument set up are similar, the 
two factors that would cause the broadening were eddy diffusion and mass transfer. 
Eddy diffusion is a term used to describe the variations in mobile phase flow and the 
analyte flow path within the chromatographic column represented in Figure 16. It is 
often related to the quality of the column packing. The larger particle size of the phenyl-
hexyl column could have led to eddy diffusion effects and thus broader peaks observed 
in the chromatogram. 
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Figure 16 Eddy diffusion effects can result in peak broadening (sourced: CrawfordScientific) 
The particle size of the phenyl-hexyl column (3.5µm) is larger than the C18 column 
(2.5µm). The difference in particle size could affect the rate of adsorption of the amines 
based on the various flow paths of the amines such that larger particles could cause a 
slowing down as the analytes traverse the column. If this was the case, one would 
expect the retention time for analytes on the phenyl hexyl column to be longer. This is 
indeed the case and therefore eddy diffusion could be an additional factor explaining the 
longer retention time on the phenyl-hexyl column. 
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 Mass transfer is dependent on the porosity of the stationary phase, where the amines 
could interact with the stationary phase at different rates of adsorption (Figure 17).  
 
Figure 17 Diagram of analyte interaction on stationary phase pore (sourced: Crawford Scientific) 
The pore diameter for both columns was 130Å, but the internal diameter of the phenyl 
hexyl column (4.6mm) was larger than the C18 column (3.6mm). The smaller diameter 
of the packing material caused an increase in linear velocity within the column. The 
increased linear velocity would have reduced the rate of mass transfer in the C18 
column, therefore decreasing peak broadening.   
Importantly it was noted that a separate peak for phenylephrine was not observed in the 
phenyl-hexyl chromatogram. Since p-synephrine and phenylephrine (m-synephrine) are 
geometric isomers, it was likely that the broad synephrine peak in the phenyl column 
was a result of the co-elution of phenylephrine and p-synephrine.  
On the basis of the above observations of greater peak resolution, decreased amount of 
peak broadening and its ability to separate the two synephrine isomers, the Xbridge 
BEH C18 was selected as the preferred column for this analysis. 
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3.3.2 Effect of pH  
 
The question being investigated here was really which effect most influenced the 
chromatography: either the unwanted silanol interactions incurred at a high pH or that 
due to having charged amines at a low pH. To answer this question three different pH 
values were tested as to their effect on chromatography– the details of which are set out 
in Table 9. 
Table 9 Summary of pH conditions respective to their modifier 
pH % Buffer/Modifier 
3 0.1% Formic acid 
10 0.1% NH4OH 
11 0.15% NH4OH 
 
Figure 18 shows a direct correlation between an increase in pH with an increased 
retention as well as peak resolution. It can be seen from the results that the separation of 
amines by RP-HPLC, is enhanced using a mobile phase pH higher than the amines’ 
pKa. As mentioned in Chapter 1, by maintaining pH above their pKa, the majority of 
the population of basic amines will be unionised which reduces interactions with the 
any exposed silanol groups on the stationary phase, reducing peak tailing and 
asymmetry (Calabuig-Hernandez, Garcia-Alvarez-Coque, & Ruiz-Angel, 2016). Note 
that many HPLC columns, however, are not stable at high pH. The ethylene bridged 
hybrid (BEH) particles of the Xbridge enable pH resistance at high pH (Waters, 2016).  
In summary, ammonium hydroxide (NH4OH) was chosen as the most suitable pH 
modifier.  
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Figure 18 Chromatographs achieved from the three pH conditions: (A) 0.1% Formic acid adjusted to pH 3; (B) ( 
Red) 0.1% Ammonium hydroxide adjusted to pH 10 (Black) 0.15% Ammonium hydroxide adjusted to pH 11.
 
--- pH 11, 0.15% 
NH4OH 
----pH 10, 0.1% 
NH4OH 
 
pH 3, 0.1% Formic 
Acid 
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However, use of ammonium hydroxide must be carefully considered. For example, a 
study by Wang et al. described studies on column oxidative dimerization of anilines to 
form azo and hydazo species (Wang et al., 2011). They similarly used an Xbridge C18 
column with ammonia as the modifier but could be duplicated on multiple columns 
capable of higher pH including Gemini NX C18 column, (Phenomenex, Torrance, CA). 
They concluded that coupling reactions are most likely caused by the oxidative reagents 
formed by the complexation of unknown elements on the surface of the Xbridge 
stationary phase and ammonia in the high pH aqueous mobile phase. A paper by Myers 
proposed a possible mechanism of the on-column reaction of N-nitrosation that occurs 
with analytes containing primary and secondary amines (such as these adrenergic 
amines) when ammonium hydroxide is used as an organic modifier (Myers et al., 2013). 
The ammonia was established to be the source of nitroso nitrogen occurring at the 
stainless steel column frit and the metal ablated from the frit. The process was thought 
to be initiated by removal of the chromium oxide protective film from the stainless steel 
by acetonitrile (Myers et al., 2013). It was suggested not to subject the working column 
to extreme pH of more than 12 as it could lead to shorter column life. 
In summary, ammonium hydroxide was selected as the pH modifier, controlled to pH 
11 as it was suitable for the determination of amines with minimal peak broadening and 
was compatible with MS detection due to its volatile nature. 
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3.3.3 Effect of Organic Modifier 
 
The extent to which the type of organic solvent and concentration thereof had on 
retention time was investigated. Acetonitrile was compared with methanol to see which 
produced the best chromatography.  
The initial gradient of mobile phases A: H2O + 0.15% NH4OH: 95 – 0% and B: Organic 
Modifier + 0.15% NH4OH: 5 – 100% over a period of 10 minutes, with a flow rate of 
1.5 mL/min at 35°C. Figure 19 shows the different chromatography achieved when 
changing between acetonitrile and methanol. Acetonitrile was observed to increase peak 
symmetry compared to methanol. This may be explained by the fact that methanol is 
protic (Harris, 2016). This could influence the way the mobile phase interacts with the 
silica surface and target components. Acetonitrile on the other hand, has lower viscosity 
would reduce the back pressure and often results in slightly better peak shape (Castells 
& Castells, 1998). The separation between tyramine and phenylephrine however was 
smaller when using acetonitrile (Figure 19). This is likely due to the higher elution 
strength of acetonitrile compared to methanol (Castells & Castells, 1998).   
Notwithstanding the above, acetonitrile was selected as the organic modifier because of 
its ability to resolve the compounds with minimal band spread and interference. A 2% 
(v/v) concentration of acetonitrile at starting conditions and gradient shift to 65% (v/v) 
was shown to completely resolve the compounds without interference from other 
components in the supplements. 
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Figure 19  Chromatographs achieved from the two organic modifiers: (A) Acetonitrile as an organic modifier and 
(B) Methanol as the organic modifier. The standard compounds are represented by: (a) Octopamine; (b) 
Synephrine; (c) Tyramine; (d) Phenylephrine 
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3.3.4 Effect of Temperature  
 
Optimising the column temperature is an important step in HPLC method development. 
The previously selected gradient was trialled with different column temperatures, 
ranging from 25°C to 40°C. Figure 20 shows a representative diagram of the effects of 
temperature on the peak formed by octopamine. The retention time of the compounds 
decreased with the increase in temperature. The higher the temperature resulted in faster 
exchange of analytes between mobile phase and stationary phase (Harris, 2016). This 
would likely result in the decreased rate of adsorption between the stationary phase and 
the amines. 
It was observed that when the temperature increased, the peak shape improved. The 
difference the gradient elution between 35° and 40° were the peak shape. The higher 
temperature reduces the viscosity of the organic phase, which would allow for a greater 
flow rate within the column (Harris, 2016). The effect of the ‘mass transfer’ at 40°C  is 
lower, as the internal flow rate increases, resulting in less peak broadening . The 
increased peak symmetry and reduced retention times lead to the selection of 40°C as 
the preferred temperature for the gradient method.  
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Figure 20 Chromatogram of octopamine peak at different temperatures on Xbridge column at 242 nm 
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3.3.5 Optimisation of UV-Vis Spectra 
 
Based on the literature, the typical UV wavelength for the amines in CA ranges between 
210-255 nm and 273-280 nm as mentioned in Chapter 1. It was determined that the λmax 
= 236 nm and 290 nm for synephrine on the spectrophotometer. A representative 
diagram is shown in Figure 21 as the λmax was similar for octopamine and tyramine. 
 
Figure 21 Representative diagram of the λmax determined for synephrine, where λmax =290 nm and 236 nm 
 
However, a Photo-diode array (PDA) was later used to further validate the optimal UV 
spectra. Contrary to the literature and the initial scan, the optimal UV for the amines 
was determined to be 242 nm for the amines of interest as shown in Figure 22. A 
possible inference for this shift in λmax was the different chemical environments of 
standards in the two detectors. It should be noted that the standards were determined 
with a gradient elution with acetonitrile and NH4OH as organic and pH modifiers whilst 
detected with the PDA. The pH of standards were at pH of 11 whilst being analysed on 
the PDA, the pH was not recorded but was assumed to be lower during the 
spectrophotometer analysis. The pH of the sample solution could have caused a shift in 
the equilibrium of the amines (Babic, Horvat, Pavlovic, & Kastelan-Macan, 2007).  The 
temperature was 35°C on the PDA analysis whereas the temperature of the 
spectrophotometer was at 25°C.  It has been noted that an increase in temperature can 
cause a decrease in maximum wavelength absorption due to the changes in π-electron 
transition at different temperatures (Yang et al., 2004).  
   
71 
n
m
220.00
240.00
260.00
280.00
300.00
320.00
340.00
360.00
380.00
400.00
Minutes
0.00 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 1.00
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
1.10
1.20
1.30
1.40
1.50
1.60
A
U
0.00 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 1.00
Minutes
250.00
300.00
350.00
 
Figure 22 UV detection on a PDA at pH 11 and 35°C where λmax = 242nm for all amines 
 
 
 
2D view   
3D view   
OCT SYN TYR 
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3.3.6 Optimisation of QDa Mass Detection 
 
Mass spectrometry (MS) has become an essential tool in analytical and pharmaceutical 
research (D’Hondt, Gevaert, Wynendaele, & De Spiegeleer, 2016). However, factors 
that limit the widespread use of MS are the high purchasing and operating costs. A high 
degree of expertise is needed for the optimisation and interpretation of MS data. The 
QDa is a miniature quadrupole-based MS that is compatible with chromatographic 
systems.  The detector is pre-optimised without the sample specific adjustments typical 
of traditional mass spectrometers (detailed in Chapter 1). A problem with working with 
a PWS matrix is the potential co-elutions from other compounds. Unlike other UV 
detectors, the use of a mass detector minimises the risk of unexpected co-elutions by 
determining compounds via its specific mass.  
Figure 23 shows the order of elution were octopamine (RT= 1.5 mins), synephrine (RT= 
2.5 mins) and tyramine (RT= 5.4 mins). The IS eluted between synephrine and tyramine 
at 4.1 minutes. Peaks were completely resolved with limited background interference. A 
starting condition blank was used to monitor signs of carryover from high concentration 
standards/samples.  
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Figure 23 Chromatograph of matrix blank and standards in a matrix blank with the elution order of Octopamine 
(t = 1.5 mins), Synephrine (t = 2.5 mins), Phenylephrine (t= 4.0 mins) and Tyramine (t = 4.4 mins). 
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One of the manipulable parameters of the QDa was the cone voltage. The cone voltages 
of 1 V-30 V were trialled and are shown in Figure 24. The cone voltage of the mass 
detector was optimised to 15 V where it had the best mass detection with the least 
amount of in-source fragmentation. 
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Figure 24 3D chromatographs of synephrine at different cone voltages; 1 V (a); 5 V (b); 15 V (c); 20 V (d); 30 V 
(e). m/z= 150 (front)and m/z= 168 (back) were observed 
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During the optimisation procedure, the positive ion mode, producing [M+H] 
+
, was 
preferred over the negative ion mode ( [M-H] 
-
 ) for these basic compounds due to the 
greater signal intensity of amines when detected in positive ion mode. Selectivity of the 
method was confirmed by comparing the elution of external standards to a mix of 
standards into a dietary supplement blank. 
The extra dimension of m/z on the Z-axis is a rapid output that aids in identifying and 
confirming the presences of the biogenic amines based on their specific masses. The 
mass spectra of the amines are represented in Figure 25. The mass of each compound 
was observed; there was a noticeable consistent fragmentation of 18 m/z for all 
compounds except for tyramine which had a mass fragment of 17 m/z. Octopamine had 
a mass of 136 and 154 m/z; synephrine and phenylephrine had a mass fragment of 150 
and 168 m/z; and tyramine was 138 and 121 m/z. The fragmentation of synephrine, 
phenylephrine and octopamine was likely a result of a [M+H - H2O] 
+
 ion cleavage on 
the β-carbon resulting in the loss of a m/z = 18. However, the fragmentation of tyramine 
was likely due to a loss of a NH3 on the alpha carbon, resulting in [M+H – NH3] 
+
 (m/z 
121). This was attributed to the ability of the p-hydroxyl group to stabilise the transition 
state on the pathway to the formation of the ion (Zhao, Shoeib, Siu, & Hopkinson, 
2006).  
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Figure 25 Mass spectra of the detected standards on a QDa with observed fragmentation occurring 
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 A representative 3-dimensional (3D) chromatographic plot depicting the mass to charge 
ratio (m/z) vs intensity for each analyte is presented in Figure 26. A MS scan was used 
to determine the presence of any contaminant or other compounds within the analytical 
range of 100 Da to 300 Da. A well-resolved separation was observed between the two 
synephrine geometric isomers, m-synephrine (phenylephrine) and p-synephrine, which 
has not been commonly observed in other studies (Roman et al., 2007; Santana et al., 
2008). These isobaric amines are difficult to resolve chromatographically due to their 
similar structures physical/chemical properties as well as identical masses (m/z 168.1) 
((Table 5), Chapter 1).  
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Figure 26 3D plot of the standards present in the spiked matrix blank with the elution order of octopamine (t = 1.5 
mins), synephrine (t = 2.5 mins), phenylephrine (t= 4.0mins) and tyramine (t = 4.4 mins) 
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Figure 27 depicts the combined representation of PWS A which had been spiked with 
100 µg/mL of each standard plus internal standard. Peak broadening, was observed in 
the case of synephrine. This suggests a degree of dispersion known as ‘overloading’ 
was present for synephrine. This seems understandable since synephrine is the major 
adrenergic stimulant in CA.  
A peak at a RT of 5.1 minutes, thought to be caffeine was detected in the PWS sample 
and subsequently supported by a mass of m/z 195.1.  Other peaks were detected at 4.6 
minutes, 4.7 minutes and 5.07 minutes; however, since their masses were greater than 
300 Da, they were not detected in the total ion chromatogram (TIC). These peaks could 
potentially correspond to other compounds such as β-Alanine and other amino acids, 
also commonly found in PWS. Similar mass fragmentation was observed in the detected 
amines; this adds a confirmatory element to the chromatographic data found. 
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Figure 27 (A) Chromatograph of standards in a CA-containing PWS sample with the elution order of Octopamine 
(t = 1.5 mins), Synephrine (t = 2.5 mins), Phenylephrine (t= 4.0mins) and Tyramine (t = 4.4 mins). (B) 3D plot of 
the standards present in the matrix blank. (C) Mass fragments of sample at 15 V. 
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3.3.7 Optimised HPLC Conditions for CA Separation 
 
Based on the optimised chromatographic and detection parameters, the final 
chromatographic conditions were determined. The optimised conditions are summarised 
in the Table 10 below:  
Table 10 Summary of optimised HPLC conditions 
Optimisation parameter Selected conditions 
Column Xbridge BEH C18 (2.5 µm, 3.0 x 100 mm) 
Organic modifier Acetonitrile 
Flow rate 1.5 mL/min 
pH 11 adjusted with NH4OH 
Temperature 40°C 
UV (λ) 242 nm 
Mass detection range (TIC) 100-300 Da 
The column used was an Xbridge C18 (2.5 µm, 3.0 x 100 mm, i.d., Waters, Ireland) 
protected by a guard column (Xbridge C18, 2.5µm, 3.0 x 20mm i.d., Waters, Ireland). 
The components were separated using a gradient elution protocol where mobile phase A 
consisted of water, mobile phase B of acetonitrile, and mobile phase C of H2O with 1% 
NH4OH. All solvents were pH adjusted to 11. The flow rate was maintained at 1.5 
mL/min while the column temperature was set to 40°C and sample temperature was set 
at 25°C. The run time was 10 minutes under gradient conditions (Table 11) based on the 
retention time of tyramine (the most non-polar of the constituents under investigation). 
The injection volume was 10 µL. There was a 5-minute delay between injections and 
UV detection was at 242 nm. Data acquisition with the QDa mass detector was 
performed in positive mode under the following conditions: total ion current (TIC) 
between m/z 100-300; capillary voltage, 3.5kV; cone voltage, 15V. Single Ion 
Recording (SIR) was set for positive mode masses of synephrine (168.2 m/z), IS (168.2 
m/z), octopamine (154.1 m/z) and tyramine (138.2 m/z). 
Table 11 HPLC separation gradient used for UV-MS analysis of caffeine and derivatives 
 
 
 
Time(min) 
Mobile phase A (Water)  
(%) 
Mobile phase B (ACN) 
(%) 
Mobile phase C (Water + 
1% NH4OH (%) 
Initial Conditions 83.0 2.0 15.0 
1.00 83.0 2.0 15.0 
7.00 20.0 65.0 15.0 
8.00 20.0 65.0 15.0 
8.50 83.0 2.0 15.0 
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3.4 Analytical Validation of CA by HPLC/UV  
 
The method validation parameters, described in Chapter 2 (Section 2.3) were in 
accordance with the ICH guidelines (ICH Expert Working Group, 1994).  
3.4.1 Linearity, LOD, LOQ 
 
Linearity was determined as a linear regression using the least-square method on a set of 
dilutions for each standard solution with phenylephrine as the internal standard.  The 
results are shown in Table 12. The linear ranges of the amines were 5 µg/mL to 100 
µg/mL. Poor linearity was observed outside this range, and the representative linearity 
curves of concentrations at 2 µg/mL and 200 µg/mL are found in Appendix 10- 12. An 
intra-day 6-point standard curve for each analyte, the slope and y-intercept, correlation 
coefficient (r
2
) and RSD % of the standard curve were determined based on the 
parameters described in Chapter 2. Figure 28 depicts the standard curves for of 
synephrine, octopamine and tyramine. The correlation coefficients were synephrine (r
2
 
= 0.998 ± 0.002), octopamine (r
2 
= 0.999±0.001) and tyramine (r
2 
= 0.997±0.003). 
Limits of detection (LOD) and Limits of Quantitation (LOQ) were determined, as 
described in Chapter 2, based on the signal-to-noise ratio (S/N) of the standards at their 
lowest concentration of 5.0µg/mL (Table 12). The LOD determined for synephrine 
octopamine and tyramine were 1.64 µg/mL, 1.50 µg/mL and 0.45 µg/mL, respectively. 
The LOQ ranged from 5.45 µg/mL, 5.00 µg/mL and 1.51 µg/mL for synephrine, 
octopamine and tyramine.   
 
Table 12 Method calibration data for linearity of synephrine, octopamine and tyramine 
Standards 
Calibration 
range 
(µg/mL) 
Linearity 
Equation 
Correlation 
coefficient 
(r2) 
LOD 
(µg/mL) 
LOQ 
(µg/mL) 
Synephrine 5.0 -100 
y = 2.6228x + 
0.971 
0.998 ± 
0.002 
1.637 5.457 
Octopamine 5.0-100 
y = 1.636x - 
0.6659 
0.999±0.001 1.501 5.004 
Tyramine 5.0- 100 
y = 1.4786x - 
4.9618 
0.997±0.003 0.454 1.514 
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Figure 28 Standard Curves for synephrine, octopamine and tyramine. Ax = area of response of analyte; AIS= area 
of IS response; [IS]= concentration of IS 
  
3.4.2 Accuracy & Precision  
 
Data presented in Table 13 was used to determine the accuracy of the method. The 
accuracy for the spiked samples varied from 77% to 107%, with standard deviations 
ranging from 0.1% to 9.4%. These values were acceptable according to the ICH, 
however further improvements were made. A matrix blank consisting of a PWS without 
CA was spiked at three concentration levels to check for the presence of peaks with 
similar retention times to the test analytes in PWS. Apart from synephrine, lower 
accuracy was observed at lower concentrations such as 5 µg/mL which was at the LOD, 
this could potentially impact the LOQ of this pilot method. This could be due to 
operator error during sample spiking as the available low volume pipette could vary in 
accuracy. Decreased accuracy was also observed at the higher end of the concentration 
range. This could be a result of column over-loading at 100 µg/mL.    
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Table 13 also depicts the results of the intra-day and inter-day precision and extraction 
recovery experiments. The intra-day precision was calculated to be between the range of 
2.1-4.1% for synephrine, 2.9-3.0% for octopamine, and 1.4 to 5.3% for tyramine. The 
inter-day precision data for synephrine was found to be between 1.5- 13.5%, 2.4-7.5% 
for octopamine and 1.5-5.2% for tyramine. RSD% values less than 15% are acceptable 
under the FDA guidelines for pharmaceutical determination. However, the 13.5% 
variation for synephrine at LOD could be improved by using a higher amount of spiked 
standard or increasing the LOD amount.  
Table 13 Intra- and Inter-day precision, accuracy and analytical recovery of standards 
Standards 
Spiked 
amounts 
(µg/mL) 
Intra-day 
precision 
(RSD %) 
Inter-day 
precision 
(RSD %) 
Recovery (%) 
(mean ± SD) 
Accuracy (%) 
(mean ± SD) 
Synephrine 5 4.2 13.4 102.8 ± 3.3 105 ± 9.0 
 
50 3.4 1.5 100.6 ± 0.2 101 ± 1.0 
 
100 2.1 1.5 93 ± 0.3 90 ± 0.1 
Octopamine 5 3 7.4 87 ± 10.8 77 ± 9.4 
 
50 3 7.5 112 ± 7.9 107 ± 1.4 
 
100 2.9 2.4 132 ± 0.2 80 ± 0.6 
Tyramine 5 5.3 5.2 82 ± 0.5 91 ± 0.7 
 
50 2.4 2.1 102 ± 1.0 106 ± 2.8 
 
100 1.4 1.5 106 ± 0.5 91 ± 0.6 
3.4.3 Recovery 
 
A matrix blank was used to determine the amount of analyte recovered after sample 
preparation (PWS without CA). 10 samples (n= 10) were prepared, spiked with standard 
solutions and extracted with the sample preparation method. Each concentration of both 
sets were analysed in 3 replicates. The percent recovery was calculated by comparing 
the peak areas of the corresponding standard solutions to the calibration curve (Figure 
28). The extraction recovery showed values between 93 to 102% for synephrine, 87 to 
132% for octopamine, and 82 to 106% for tyramine amines. The yield recoveries above 
100% could potentially be caused by pipetting inconsistencies. Increasing the sample 
size could help reduce the effects of these errors. At lower concentrations, the amounts 
of analyte recovered were lower than the higher spiked concentrations except for 
synephrine. This could possibly be due to loss during sample preparation (Poole, 2003).  
This could be resolved by using a higher concentration of non-polar solvent during the 
sample preparation. 
 
   
82 
3.5 Quantification of Adrenergic Amines in CA-containing PWS. 
 
Table 14 details the quantities of adrenergic amines determined in the PWS samples per 
gram as well as per respective serving size. The p-synephrine content within the PWSs 
analysed varied from 0.15 mg/g to 0.89 mg/g; octopamine on average 0.16 mg/g; and 
tyramine averaged at 0.4 mg/g. The concentration of p-synephrine was in agreement 
with other reported methods of between 0.001 mg/g to 8.65 mg/g (Avula, Upparapalli, 
Navarrete, et al., 2005; Ganzera et al., 2005; Marchei et al., 2006; Pellati & Benvenuti, 
2007; Pellati et al., 2002; Roman et al., 2007; Slezak et al., 2007).  
A standard reference material of CA (SRM 3258) contained 8.65 mg/g of synephrine, 
0.14 mg/g of octopamine and 0.026 mg/g of tyramine (Putzbach et al., 2007). The ratios 
of biogenic amine found within were used as a reference to contrast with the analysed 
supplements. The difference in concentration of p-synephrine determined was likely due 
to the lack of uniformity and lot-lot variability of PWS manufacturing (Slezak et al., 
2007)   
Supplement B (360Rage) and D (ErgoBlast) had the highest amount of octopamine of 
44 mg/serve. In Australia, there are currently no legal maximum limits for octopamine 
concentration in dietary supplements octopamine is found naturally in CA extracts in 
amounts between 0.12 mg/g to 0.8 mg/g (Sander et al., 2008). It was evident that it was 
not in agreeance to the ratios found in a SRM. The high amount of octopamine 
determined in this study suggests it may have been added rather than from that within 
the plant extract. Octopamine is a banned substance for use in athletic competitions due 
to its stimulatory properties whereas synephrine is a monitored substance (World Anti-
doping Agency, 2015).  
Tyramine is not listed on any of the labels of the supplements tested. The highest 
amount of tyramine quantified in the tested PWS was 0.69 mg/g (PumpHD). The FDA 
suggests an acceptance level between 100-800 mg/g, and a toxicity level over the 
amount of 1080 mg/kg tyramine intake (Nout, 1994). Tyramine has been used as an 
experimental tool to study the mechanisms of noradrenaline release from sympathetic 
neurones and as an index of peripheral sympathetic nerve function (Broadley, 2010). 
Note the quantified levels of tyramine are higher than the ones present in the previously 
mentioned SRM 3258. It is possible that tyramine determined in this supplement was 
also added to enhance the overall stimulatory effect of the PWS. 
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Table 14 Synephrine, Octopamine and Tyramine content in PWS (mg/g) (mean ± RSD %) 
  
Samples 
Amount of amines found in PWS 
(mg/g) (mean ± RSD %)   
Amount of amines found in PWS 
(mg/serve) (mean ± RSD %) 
Synephrine Octopamine Tyramine   Synephrine Octopamine Tyramine 
A 
(MusclePrime) 
 
0.25 ± 9.3 0.10 ± 10.2 0.10 ± 2.5 
 
4.69 ± 9.3 1.97 ± 10.2 1.95 ± 2.5 
B 
(Gold-
Standard 
Preworkout) 
 
0.31 ± 5.6 4.46 ± 12.7 0.52 ± 0.4 
 
3.11 ± 5.6 44.62 ± 12.7 5.17 ± 0.4 
C (360Rage) 
 
0.15 ± 2.9 0.28 ± 4.6 0.28 ± 1.1 
 
1.06 ± 2.9 2.03 ± 4.6 2.05 ± 1.1 
D (ErgoBlast) 
 
0.70 ± 1.5 8.90 ± 10.1 0.28 ± 2.0 
 
3.49 ± 1.5 44.52 ± 10.1 1.39 ± 2.0 
E (PumpHD) 
 
0.89 ± 1.8 0.65 ± 3.8 0.69 ± 3.9 
 
8.30 ± 1.8 6.54 ± 3.8 6.90 ± 3.9 
 
3.6 Conclusion  
 
A simple, rapid procedure to determine levels of synephrine, octopamine and tyramine 
in CA-containing PWS has been presented. The procedure involved a HPLC-UV/MS 
method with a total run time of 10 minutes on a C18 Xbridge column. Neither extensive 
derivatization nor sample preparation procedures were required. The amounts of 
synephrine found were 0.25 – 0.89 mg/g comparable to other studies ranging from 
0.001 mg/g to 8.65 mg/g (Avula, Upparapalli, Navarrete, et al., 2005; Ganzera et al., 
2005; Marchei et al., 2006; Pellati & Benvenuti, 2007; Pellati et al., 2002; Roman et al., 
2007; Slezak et al., 2007). However, octopamine and tyramine were found in higher 
amounts than standard reference materials at 8.9 mg/g and 0.69 mg/g.  
It was difficult to compare the exact amount of octopamine and tyramine as most of the 
CA was labelled under a proprietary blend. Octopamine is a doping substance that is 
illicit in sport when detected in urine. According to Thevis et al. (2012), octopamine 
was eluted at concentrations at an order of magnitude less from the consumed amount. 
The LOD/LOQ determined for this method is such that its usability could also be 
extended to PWS screening for concentrations of octopamine and synephrine in 
biological matrices such as urine for doping analyses as it was in agreeance to Thevis et 
al. (2012).  
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  A Rapid HPLC-MS Protocol Chapter 4
for Caffeine and Dimethylxanthines in 
Pre-workout Supplements 
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4.1 Background 
 
Significant stimulatory effects from the consumption of PWS is provided by the 
xanthine component, specifically caffeine (1,3,7-trimethylxanthine) and the 3 
dimethylxanthines (DMX). These compounds have become an accepted and prevalent 
dietary constituent for many people and, with increasing evidence of adverse effects 
arising from overconsumption, regulatory bodies have sought to impose limits on their 
incorporation into foods and supplements. Caffeine is the only methylxanthine subject 
to specific product labelling requirements – the details of which vary depending on 
country of manufacturing origin. In Australia products containing caffeine are required 
to state the amount and also carry a warning. A recent review on caffeine toxicity 
suggested that undeclared herbal components in most supplements could expose 
consumers to an increased risk of caffeine toxicity (Musgrave et al., 2016). The multi-
stimulant component nature of PWS is a potential factor contributing to the delay in 
attributing specific adverse effects to one compound or another. Such increased PWS 
consumption beyond athletes and fitness enthusiasts into recreational use by the general 
population (Gibson, 2014), and concomitant the increased adverse health reports may 
result in more stringent caffeine content/labelling requirements leading to an increased 
demand for analysis of products and/or biological samples. It is therefore important to 
develop an accurate, rapid, cost-effective, sensitive and transferrable method for the 
detection and quantification of caffeine and the DMX isomers that may be suitable for 
both supplement and biological matrices.  
A number of analytical methods have been used for the analysis and quantification of 
caffeine and its DMX derivatives. A search of the literature revealed that RP-HPLC-UV 
was the most common analytical method used for caffeine and DMX analysis. 
Beauchamp et al. sourced 9 caffeine-containing PWS products using LC–quadrupole 
time-of-flight MS (QTOF/MS) using an Agilent Poroshell C-18 column (2.1 x 100 mm, 
2.7 µm), on a 12 minute gradient of water and acetonitrile adjusted with 0.05% formic 
acid, was used to identify and quantify substances in the PWS samples. The average 
caffeine recovery was 88.25 ± 13.41% compared to the labelled caffeine content 
(Beauchamp et al., 2016). The additional use of a TIC confirmed the absence of any 
other stimulants based on their current database of 45 amphetamines and 8 
phenethylamines. Chromatography conducted by the Beauchamp method was 
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performed on a UPLC system which, while sensitive, has high setup and operating 
costs. A more cost effective method of caffeine and DMX analysis is HPLC-UV which 
is likely responsible for the prevalence of published methods using this technique. 
Recent studies suggested good chromatographic results, approaching that seen in 
UPLC,  can be achieved on a HPLC system by using  stationary phases with small 
particle size such as 2 µm (DeStefano, Boyes, Schuster, Miles, & Kirkland, 2014; 
Swartz, 2005).  
A number of researchers, however, have noted difficulty in separating the three DMX 
isomers by RP-HPLC (Randon et al., 2010). The three DMX are configurational 
isomers (Figure 2, Chapter 1) and therefore have identical masses. This presents a 
challenge for analytical separation without involving costly and time-consuming 
derivatization protocols. Most methods which involve separation of caffeine in food do 
not report the separation of paraxanthine (PX) and theophylline (TP) (Bispo et al., 2002; 
Hasegawa et al., 2009; Kanazawa et al., 2000; Martinez-Lopez et al., 2014; Thomas et 
al., 2004). This may be because PX is not derived from plant products. Bispo et al., 
developed a method to determine caffeine, TB and TP in beverages and urine samples 
using HPLC-UV. The method involved a Bondesil C18 column with a methanol-water-
acetic acid gradient at 0.7 mL/min and UV detection at 273 nm. The LOD was 0.1 
pg/mL for all three methylxanthines. This method was versatile enough to be used for 
levels up to 350 µg/mL of caffeine, 32 µg/mL of TB and 47 µg/mL of TP. This method 
did not involve additional sample derivatization but was not specific for PX, the main 
metabolite of caffeine. The incorporation of mass detection would enhance structure 
confirmation for the DMX derivatives, especially when present in a urine matrix. Our 
strategy, employing a RP-HPLC system with combined UV and in-line QDa mass 
detector aimed to confirm the identity and masses of all four compounds without 
derivatisation. Additionally, we aimed to achieve sufficiently high sensitivity as to 
allow the method to be transferable between various matrices, either biological matrices 
or supplements  
The aim of this present study was to develop a rapid and adaptable HPLC-UV/MS 
method for the determination and quantification of caffeine and its DMX derivatives, 
paraxanthine (PX), theobromine (TB) and theophylline (TP) and apply it to the analysis 
of these compounds in a variety of Australian-manufactured and overseas-sourced 
PWS. 
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4.2 Experimental 
4.2.1 Chemicals and Reagents  
 
The chemicals and reagents used in this chapter are detailed in General Methods 
(Chapter 2, section 2.2). The 5 PWS selected were KardioFire (A); 360Rage (360°Cut 
Performance Supplements) (B); PumpHD (BPISports) (C); MusclePrime (AllMax 
Nutrition) (D) and DyNO (RSP Nutrition) (E). The PWS samples A, B and D were 
purchased online (manufactured in the USA) while samples C and E were sourced from 
a local health store in South-East Queensland, Australia. 
4.2.2 Standard Preparation 
 
Stock solutions (1 mg/mL) were prepared for all standards as well as internal standard 
(IS) and stored in 4°C until analysis. Etofylline (7-(2, hydroxyethyl) theophylline) is a 
synthetic structural analogue of the natural methylxanthines and has been used in 
previous chromatographic methods (Buyuktuncel, 2010; Johansson, Gronrydberg, & 
Schmekel, 1993; Kanazawa et al., 2000; Naline, Flouvat, Advenier, & Pays, 1987; 
Nirogi, Kandikere, Shukla, Mudigonda, & Ajjala, 2007). A linear dilution was prepared 
for each standard between 1 µg/mL and 200 µg/mL. The results of concentrations 
outside this linear range will be discussed in section 4.4.1. The PWS samples were 
prepared using the SPE method detailed in Chapter 2.  
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4.3 Method Development 
 
Following the method development process depicted in Figure 8 (Chapter 2), various 
parameters such as different column chemistries, mobile phase composition, 
temperature and gradient combinations were optimised prior to the quantification of 
xanthines in PWS.  
The details of this process are outlined in the following sections to attain the best 
conditions for separation. 
4.3.1 Effect of Column Chemistries 
 
To compare the effect on analyte retention of the two columns a series of 100µg/mL 
standard mix injections were run using an initial mobile phase gradient A) 0.1% Formic 
Acid: 95 – 0% and B) 0.1% Formic Acid: 5 – 100% over a period of 10 minutes with a 
flow rate of 1mL/min at 30°C The two columns tested were a T3 HSS C18 column (5 
µm, 3.0 x 150 mm, i.d.) and a Xselect CSH phenyl-hexyl (3.5 µm, 4.6 x 100 mm, i.d.). 
The phenyl-hexyl column showed higher resolution than the C-18 column. This could 
be due to increased π-π interaction that allows superior retention (Gibson & Fowler, 
2014). 
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Figure 29 Comparison of columns: (A) Xselect CSH phenylhexyl (3.5µm, 4.6 x 100mm, i.d.) and (B) T3 HSS C18 
(5 µm, 3.0 x 150 mm, i.d.). The standard compounds are represented by: (a) TB; (b) PX; (c) TP; (d) caffeine 
The elution order of the xanthines from the two columns was TB, PX, TP followed by 
caffeine (Figure 29). The results of the chromatography are summarised in Table 15. 
The order correlates well with the predicted order of elution given the dielectric for each 
compound (See, Table 3 of Chapter 1). 
Table 15 Summary of effects of column chemistry on Caffeine and DMX 
Compound RT on Phenyl-hexyl column 
(mins) 
RT on HSS T3 column  (mins) 
Theobromine 3.72 4.14 
Paraxanthine 4.45 5.26 
Theophylline 4.69 5.59 
Caffeine 5.71 7.55 
 
 
Phenyl-Hexyl (4.6x 100 mm, 3.5 µm) 
HSS T3 C18 (5.0 x 150 mm, 3.0 µm) 
a b 
c 
d 
a 
b 
c 
d 
A 
B 
   
92 
The peaks observed on the C18 chromatogram were broader than those seen on the 
phenyl-hexyl. As previously discussed, a number of factors could contribute to peak 
broadening. The particle size of the C18 column (5 µm) was larger than the particle size 
of the phenyl-hexyl (3.5 µm) column. Eddy diffusion could explain the observed peak 
broadening since the larger particle size of the C18 column could result in a slower rate 
of analyte flow.  
An increased RT was observed for the analytes on the phenyl-hexyl column. The phenyl 
functional group of the phenyl-hexyl column could introduce potential π-π stacking 
interactions which would cause analytes to be retained longer on the phenyl-hexyl 
column (Yang et al., 2005). However, there are additional factors that could explain the 
longer retention time in the C18 column. The pore diameters for both columns were 130 
Å, but the internal diameter of the phenyl hexyl column (4.6 mm) was larger than the 
C18 column (3.0 mm). The smaller internal diameter of the packing material would 
have resulted in a slightly higher flow rate in the C18 column to decrease peak 
broadening. However, the C18 column was longer (150 mm) than the phenyl-hexyl 
column (100 mm). The 50 mm difference in column length could increase the rate of 
interaction between stationary phase and xanthines in the C18 column. 
Both columns were able to partially separate the isomers, TP and PX. However, further 
developments will be discussed in later sections of this chapter. On the basis of the 
observed shorter retention times and decreased amount of peak broadening, the Xselect 
phenyl-hexyl column was selected as the preferred column for this analysis. 
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4.3.2 Effect of pH  
 
Caffeine and the DMXs have two to three of its four nitrogen bonds methylated, and 
can only serve as a weak hydrogen bond acceptor. The conjugate acid of caffeine has a 
pKa of -0.16, which means at acidic pH, a majority of the caffeine species will be in the 
deprotonated form. In contrast to the analysis of the amines, caffeine and DMX are 
neutral at pH 2. The two acidic modifiers trifluroacetic acid (TFA) and formic acid (FA) 
were tested to confirm which would produce superior chromatography.  
Better peak resolution was observed with TFA (Figure 30). The retention of the 
xanthines with the two pH modifiers was relatively similar. However, TFA also causes 
ion suppressing effects during MS which results in signal reduction (Annesley, 2003). 
For this reason, formic acid was selected as an alternative modifier to TFA as it was a 
volatile modifier capable of producing good peak shape at pH 3.   
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Figure 30 Chromatographs of caffeine and dimethylxanthine adjusted to pH 3 (0.1% formic acid) and pH 2 (0.1% 
TFA). The standard compounds are represented by: (a) TB; (b) PX; (c) TP; (d) caffeine 
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4.3.3 Effect of Sampling Rate  
 
The sampling rate of the UV-Vis detector produced interesting results on peak 
resolution. Studies based on the accuracy of the numerical integration of peak area 
report that at least 10 data points per second were required when a Gaussian peak was 
digitized (Wahab et al., 2016).  
The results from an initial sampling rate of 1 point/second are shown in Figure 31. This 
was the default sampling rate used in earlier investigations for xanthine analysis 
producing relatively broad, non-Gaussian peaks for all the analytes. However, when the 
sampling rate was increased to 40 points/second, there was a noticeable increase in peak 
resolution and symmetry. A detailed description of the theory of data acquisition is 
beyond the scope of this study however for a description of the importance of sampling 
rate has been reported by Wahab et. al (2016). With the increased improvement in peak 
shape of the analytes, a sampling rate of 40 points/second was used for further 
optimisation steps.  
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Figure 31 Chromatographs of caffeine and DMX at 1 point/sec and 40 point/sec 
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4.3.4 Effect of Organic Modifier 
 
The extent to which the type of organic solvent and concentration thereof had on 
retention time was investigated. Acetonitrile was compared with methanol to see which 
produced the best chromatography. Etofylline was added to the standard mix of caffeine 
and DMX to observe the changes in resolution with organic modifier use. 
Figure 32 shows the differences in chromatography produced by changing between 
methanol and acetonitrile. A narrower peak width was observed for TP and PX when 
using acetonitrile compared to methanol. More hydrogen bonds occur between 
methanol and TP/PX which allowed greater separation between the two compounds. A 
15% (v/v) amount of methanol at starting conditions and gradient shift to 60% (v/v) was 
shown to completely resolve the compounds without interference from other 
components in the supplements.  
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Figure 32 Chromatographs achieved from the two organic modifiers: (A) Acetonitrile as an organic modifier and 
(B) methanol as the organic modifier. The standard compounds are represented by: (a) TB; (b) PX; (c) TP; (d) 
caffeine;(e) etofylline 
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4.3.5 Effect of Temperature  
 
Optimising the column temperature is an important step in HPLC method development. 
The previously selected gradient was trialled with different column temperatures, 
ranging from 20°C to 35°C. Figure 33 shows a representative diagram of the effects of 
temperature on the peak formed by caffeine. It was observed that there was a decrease 
in retention time and improvement in peak shape as the temperature increased. The 
higher temperature reduces the viscosity of the organic phase, which would allow for a 
greater flow rate within the column (Harris, 2016). However, at 35°C, the separation 
between TP and PX decreased. This could be caused by the decreased rate of mass 
transfer of the two isomers on the stationary phase with the increased laminar flow. 
However, further improvements on temperature optimisation could be achieved by 
plotting the separation factor (k) values and comparing it based on the resolution 
equation (R) (Equation 1, Chapter 2). 
 As a result of the good peak symmetry, capability to separate TP and PX and reduced 
retention times, 30°C was the preferred temperature for the gradient method.  
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Figure 33 Chromatogram of the effect of temperature on the separation of caffeine on phenyl-hexyl column  
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4.3.6 Optimisation of the UV-Vis Detector  
Based on a search of the literature, the most prevalent wavelength for the analysis of 
caffeine in dietary chromatography ranged between 270 nm and 280 nm as mentioned 
in Chapter 1. The maximum wavelength (λmax) for caffeine was determined for caffeine 
and DMX on a Beckman UV spectrophotometer and found to be 272 nm. (Data not 
shown) 
4.3.7 Representative Chromatograms  
 Figure 34 shows the order of elution was TB, PX, TP, etofylline and caffeine with the 
retention times of 3.8, 4.7, 5.0, 5.4 and 6.3 minutes respectively. Peaks were completely 
resolved with limited background interference. A water blank was used to monitor signs 
of carryover from high concentration standards/samples.   
 
Figure 34 Representative chromatograms or caffeine and DMX standards at high concentrations of (100 µg/mL) 
(top); chromatogram of caffeine present in pre-workout supplement A (middle); and chromatogram of caffeine, 
TP and PX present The approximate retention times: TB= 3.7 min, PX= 4.6 min, TP= 4.9 min, etofylline (I.S.) = 
5.3 min and caffeine= 6.2 min. On phenyl-hexyl column at λ=272 nm 
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Selectivity of the method was confirmed by UV-detection and QDa-MS by injecting a 
starting condition blank and a dietary supplement blank. Representative 3-dimensional 
(3D) chromatographic plot depicting the additional dimension of mass to charge ratio 
(m/z) is presented in Figure 35, where the standards are colour coded into the following; 
caffeine (red); IS (blue); TB, TP, and PX (green). The m/z aids in identifying and 
confirming the presence of the methylxanthines by specific masses.  
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Figure 35  3D chromatogram/ mass plot. X-axis =time (min), Y-axis =Intensity of m/z signal, Z-axis = mass to 
charge ratio (m/z). Caffeine (red); TB, PX, and TP (green); etofylline (blue) is present in standards (left). 
Whereas only caffeine and etofylline is present in the spiked pre-workout sample A (right) 
The specific masses detected at the apex of individual compounds (Figure 36) were 
detected simultaneous to the UV spectra (Figure 37). TIC was used to describe the 
presence of any minor components that were overlooked within the range of 100Da to 
600 Da. The SIR was set to the masses of m/z 181.1, for the detection of TB, TP and 
PX; m/z 195.1 for the detection of caffeine; and m/z 225.1 for the detection of etofylline. 
The method showed well-resolved separation between PX and TP, not commonly 
observed in other studies (Bispo et al., 2002; Hasegawa et al., 2009; Kanazawa et al., 
2000; Martinez-Lopez et al., 2014; Thomas et al., 2004). These isobaric DMXs are 
difficult to resolve due to their chemical similarities and identical mass (m/z 181.1). 
Since PX is not derived from plants and therefore not expected in PWS, its detection 
was not specifically determined. Whilst this is most likely true in the case of PWS, 
developing a rapid method which does resolve these compounds provides a distinct 
advantage in specificity as well as being adaptable to biological matrices. 
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Figure 36 Mass detected at individual peaks of compounds, TB, PX, TP, etofylline, and caffeine 
  
 
Figure 37 Chromatogram of standards (top) coupled with the Total Ion Chromatogram (TIC) scanning from a 
range of 100 Da to 600 Da (middle) and Single Ion recording (SIR) of respective compounds 
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4.3.8 Optimised HPLC/UV-MS Procedure 
 
 Based on the optimised chromatographic and detection parameters, the final 
chromatographic conditions were determined. The optimised conditions are summarised 
in the Table 16 below:  
Table 16 Summary of optimised HPLC conditions 
Optimisation 
parameter 
Selected conditions 
Column Xselect CSH phenyl-hexyl  
(3.5 µm, 4.6 x 100 mm) 
Organic modifier Methanol 
Flow rate 1 mL/min 
pH 3.0 adjusted with formic acid 
Temperature 30°C 
UV (λ) 272 nm 
Mass detection range 
(TIC) 
100-600 Da 
 
The chromatographic column used was an Xselect CSH phenyl-hexyl (3.5 µm, 4.6 x 
100 mm, i.d., Waters, Ireland) protected by a guard column (Xselect CSH phenyl-hexyl 
3.5µm, 4.6 x 20 mm). The components were separated using a gradient elution protocol 
where mobile phase A consisted of a mixture of water with 0.1% formic acid whilst 
mobile phase B comprised methanol with 0.1% formic acid. Both solvents were pH 
adjusted to 4.5.  
The flow rate was maintained at 1 mL/min while the column temperature was set to 
30°C and sample temperature was set at 25°C. The run time was 10 minutes under 
gradient conditions (Table 17) based on the retention time of caffeine (the most non-
polar of the constituents under investigation). There was a 3-minute delay between 
injections and UV detection was at 272 nm.  
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Data acquisition with the QDa mass detector was performed in positive mode under the 
following conditions: total ion current (TIC) between m/z 100-600; capillary voltage, 
3.5 kV; cone voltage, 15 V. Single Ion Recording (SIR) was set for positive mode 
masses of caffeine (195.1), IS (225.2) and respective derivatives (181.5).  
Table 17 HPLC separation gradient used for UV-MS analysis of caffeine and derivatives 
Gradient elution 
 
Time(min) 
Mobile phase A 
(Water + 0.1% 
Formic Acid) 
  (%) 
Mobile phase B 
(Methanol + 
0.1% Formic 
Acid) 
 (%) 
0 85 15 
5 70 30 
5.5 85 15 
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4.4 Method Validation  
 
The method validation parameters were highlighted in the Methods chapter (Section 
2.3). Where the method was validated according to the ICH guidelines (ICH Expert 
Working Group, 1994) 
4.4.1 Linearity  
 
Linearity was determined using the least-square method (linear regression) for each of 
the standards. The assay showed linearity between the range 1 µg/mL to 200 µg/mL as 
reported in Table 18. The loss of analyte beyond 0.1 µg/mL was amplified and resulted 
in poor linearity, whereas concentration of 500 µg/mL resulted in peak overload and 
poor correlation coefficient (data not shown). Figure 38 shows a chromatogram of the 
xanthines at 8 concentration levels. Standards were injected at the beginning of each 
sample injection sequence and after every 10 sample injections, and at the end of each 
sequence. This provided an intra-day 8-point standard curve generated with each 
analyte, the slope and y-intercept, correlation coefficient (r
2
) and %RSD of the standard 
curve (Figure 38). Linearity was observed in this range for each compound (correlation 
coefficients (r
2) ≥ 0.9998 for all except for TB which had an r2 ≥ 0.9914). The deviation 
TB’s correlation coefficient could be an issue of one concentration point (50 µg/mL) ( 
Figure 39). This could be a result of a random error cause by improper pipetting.  
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Figure 38 Chromatograph of caffeine and 3 DMX standards at 8 different concentrations 
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Figure 39  Intra-day 8 point standard curve for TB. Points represent average of 3 replicates 
 
4.4.2  Detection and Quantification Limits  
 
LOD and LOQ were determined based on their respective signal-to-noise ratio (S/N) of 
the standards at their lowest concentration of 0.1 µg/mL, where the desired S/N for the 
LOD is 3:1, whereas the desired S/N for the LOQ is 10:1 (Table 18). The LOD of the 3 
DMX ranged from 0.02 to 0.4 µg/mL whereas the LOD determined for caffeine was 2.1 
µg/mL and LOQ of 6.5 µg/ mL. The higher LOD of caffeine would suggest that the 
concentrations of less than 5 µg/mL were not suitable for linear calibration. However, 
this could be improved by avoiding low volume pipette injection, as there could be 
potential loss of caffeine at 1µg/mL. The reported amounts of caffeine and its DMX 
derivatives found in urine, ranged from 2 µg/mL to 15 µg/mL, which give potential for 
this method to be used for caffeine analysis in biological fluids (Buyuktuncel, 2010). 
The LOD and LOQ also make this method suitable for caffeine doping analysis in sport 
where 12 µg/mL of caffeine is considered a doping agent when this amount is found in 
urine (Del Coso, Muñoz, & Muñoz-Guerra, 2011). 
Table 18 LOD/ LOQ for caffeine and derivatives 
Standards 
Calibration 
range 
(µg/mL) 
Correlation 
coefficient 
(r2) 
LOD 
(µg/mL) 
LOQ 
(µg/mL) 
Caffeine 0.1-200 0.999±0.002 2.19 6.46 
Etofylline 0.1-200 0.999±0.001 0.10 0.31 
Paraxanthine 0.1-200 0.999±0.002 0.02 0.07 
Theobromine 0.1-200 0.991±0.004 0.47 1.43 
Theophylline 0.1-200 0.999±0.003 0.09 0.28 
 
 
Theobromine (r2= 0.9914) 
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4.4.3 Precision 
 
The repeatability was determined by preparing 8 replicates of standards at 100µg/mL. 
The results are reported in Table 19 with the %RSD. Repeatability, according to the 
association of analytical chemists (AOAC) should not exceed 1.25% RSD, our 
repeatability values were considered satisfactory for the retention times as indicated by 
%RSD range of 0.06 – 0.25%, peak height ranging from 1.11 -1.14% and also the peak 
area indicated by the %RSD range of 0.40-0.59%. This indicates that for a single-
laboratory assay acceptable precision was achieved. However, additional validation by 
incorporating ‘between laboratory’ testing for parameters such as intermediate precision 
would be further strengthen the overall validation of this method.  
Table 19 Intra-day precision assay of standard and analytical recovery of IS in samples 
Analyte Repeatability ( n = 8, mean)       
 
RT 
(min) 
%R.S.D  
Peak area (x106) (mean + S. 
D.) 
%R.S.D  
Peak Height (x105) (mean + S. 
D) 
%R.S.D  
Caffeine 6.31 0.06 2.89±0.01 0.4 5.76 ±0.70 1.21 
Paraxanthine 4.73 0.14 2.54±0.01 0.43 5.51 ±0.06 1.14 
Theobromine 3.81 0.25 3.44 ± 0.02 0.54 7.67 ± 0.06 1.21 
Theophylline 5.01 0.14 3.30 ± 0.02 0.59 6.79 ± 0.08 1.15 
Etofylline 5.44 0.13 2.55 ± 0.01 0.55 5.39 ± 0.06 1.11 
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4.4.4 Accuracy   
 
Within-batch accuracy evaluations were determined by spiking PWS with etofylline 
(IS) Accuracy was assessed using 3 concentrations (5, 25 and 50 µg/mL) of I.S on 3 
separate days.  The standards were prepared in triplicate at each level of concentration. 
The quantitative recoveries are shown in Table 20 where the recoveries ranged from 
81.8 – 89.2%, with %RSD 0.5 – 2.57%. The recoveries obtained after solid phase 
extraction at different concentrations showed that there were only slight variations 
within supplements and the results obtained for intra-assay accuracy based on etofylline 
were satisfactory (ICH Expert Working Group, 1994).  
Table 20 Analytical recovery of etofylline (IS) spiking in PWS 
Amount 
of Spiked 
IS 
(µg/mL) 
Determined 
amount of 
IS (µg/mL) 
Recovery 
of IS (%) 
(mean ± 
S. D., 
n=3) 
%R.S.D  
5 4.09 
81.78 ± 
5.30 
2.57 
25 22.3 
89.20 ± 
1.89 
0.50 
50 44.1 
88.19 ± 
5.17 
1.10 
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4.5 Determination of Caffeine and DMX in PWS samples  
 
The RP-HPLC-UV/MS method described was used for the quantitative determination of 
caffeine and DMX in a set of PWS samples. The results are shown in Table 21 as mean 
and standard deviation (S.D.) of three replicate samples in the same batch. The 
concentration of caffeine quantified ranged from 9.89 mg/g size to 25.30 mg/g size. TB 
was present in products A, D and E. TP and PX were present (at low levels) only in 
supplement C, which did not contain TB.  
 
Table 21 Caffeine and methylxanthine content (mean± S.D., n= 3) in dietary supplements 
Products 
Caffeine 
(mg/g)  
Theobromine 
(mg/g) 
Theophylline 
(mg/g) 
Paraxanthine 
(mg/g) 
A 
(KardioFire) 
 
20.10 ± 
1.81 
1.12 ± 0.15 N/A N/A 
B 
 (360Rage) 
 
15.70 ± 
1.53 
N/A N/A N/A 
C 
 (PumpHD) 
 
25.30 ± 
1.21 
N/A 0.31± 0.02 0.03 ± 0.01 
D 
(MusclePrime) 
 
9.89± 
0.39 
2.57 ± 5.77 N/A N/A 
E 
 (DyNO) 
 
24.00 ± 
0.16 
3.03 ±  0.10 N/A N/A 
 
A comparison was made between the levels of caffeine and DMX in the sample set of 
PWS and that found on their labels (if present) (Table 22). The amount of caffeine 
determined was calculated to reflect per serving quantity to compare directly with the 
labelled dose which varied from 7 g to 19 g.  Caffeine was not listed on the label of 
product A despite containing 201 mg of caffeine. Products B and C listed caffeine to be 
present as part of a proprietary blend where 157 mg of caffeine was found in product B 
and 192 mg of caffeine was found in product C. The labels of the products D and E 
listed caffeine in the form of ‘caffeine anhydrous’ as 100 mg and 300 mg respectively, 
the amount of caffeine determined in product D was 188 mg/dose while 180 mg/dose 
was found in product E.   
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Table 21 clearly shows evidence of the presence of PX in one of the randomly selected 
PWS, albeit in low amounts. Since it is a primary metabolite of caffeine and found in 
much higher levels than caffeine in plasma or urine samples, separation from TP was 
imperative to avoid over estimation of TP. While a complete understanding of the 
physiological effects of PX are not well researched reports of increased skeletal muscle 
contractility have been described (Hawke et al., 2000; Orru et al., 2013). An additional 
source of TP and PX could be attributed by the actions of filamentous fungi. Hakil et.al 
observed the demethylation of caffeine to TP via the Aspergillus and Penicillium genus 
strains of fungi (Hakil, Denis, Viniegra-González, & Augur, 1998). PumpHD contains 
Theobroma cacao extracts likely to be the source of caffeine. Potential degradation of 
caffeine to these DMX compounds could occur during the storing or processing phase 
of product manufacturing. The purity and potential co-elution of the compounds were 
monitored by tracking the masses found in the leading, apex and tailing of each peak. 
The advantage of incorporating a quadrupole mass detector can be observed in the form 
of peak purity at the apex in Figure 35. Mass spectral data was used to identify the 
components with unique masses in the mixture such as caffeine (m/z 195.2) and 
etofylline (m/z 225.2). However, confirming the presence of the isobaric DMX (m/z 
181.2) required combining completely resolved peaks from UV data and mass 
detection. 
Table 22 Amount of caffeine present compared to respective label contents 
Products 
Amount 
of 
Caffeine 
Quantified 
(mg/mL) 
Caffeine listed 
on the label 
(mg) (per 
serving size) 
Actual 
amount of 
caffeine 
(mg)(per 
serving 
size) 
A 
(KardioFire) 
 
20.10 ± 
1.81 
Not listed 
201.44 ± 
18.1 
B 
 (360Rage) 
 
15.70 ± 
1.53 
Proprietary 
Blend 
156.96 ± 
15.3 
C 
 (PumpHD) 
 
25.30 ± 
1.21 
Proprietary 
Blend 
189.60 ± 
9.06 
D 
(MusclePrime) 
 
9.89± 
0.39 
100 
187.89 ± 
7.14 
E 
 (DyNO) 
 
24.00 ± 
0.16 
300 
179.86 ± 
1.20 
 
   
108 
4.6 Application and Usability of the Method  
 
The FDA takes a liberal approach to the control of caffeine content and labelling in 
dietary supplements whereby caffeine is only required to be listed as an ingredient. In 
some other countries such as Australia, however, caffeine-containing dietary 
supplements, such as PWS, fall outside the jurisdiction of the Food Standards Code of 
Australia and often contain amounts that would otherwise breach the Code (For 
example, an energy drink is allowed to have a maximum of 80 mg/serving) ("Australia 
New Zealand Food Standards Code – Standard 2.9.4 – Formulated supplementary sports 
foods," 2016). Instead, as complementary medicines, these products are regulated by the 
TGA and must state the quantity per dose as well as carry a safety warning for 
vulnerable populations such as those under 18 years or who are pregnant. As 
highlighted in Table 22, the supplement with the highest caffeine content (201 mg) 
(Supplement A) did not list caffeine on its label. Furthermore, for those products that 
quoted specific amounts, much higher levels of caffeine were detected (except for 
supplement E).  
PX was specifically found in supplement C albeit in low levels, which was surprising 
since, as previously mentioned, it is not a plant based compound. Understandably, no 
specific listings for any of the DMX were present on the PWS labels - manufacturers 
having no such requirement to do so by either the FDA or the TGA. Caffeine is often 
mentioned as part of a ‘proprietary blend’ where only the weight of the total blend is 
required to be listed (U.S. Food and Drug Administration (FDA), 1994). The 
discrepancy between the stated quantities and those quantified here not only makes it 
difficult for people to discern their total daily stimulant intake but also raises concerns 
for the public health and safety of consumers due to the potential for adverse effects. 
This analysis highlights a discrepancy between labelled and actual caffeine content and 
provides support for an argument for tighter regulation. 
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4.7 Conclusion 
 
We have developed a simple, rapid procedure to determine levels of caffeine and the 
three DMX derivatives, TB, PX and TP in PWS. The procedure involved a HPLC-
UV/MS method that has a total run time of 10 minutes. Recently, a number of studies 
used HPLC (Andrews et al., 2007; Hadad, Salam, Soliman, & Mesbah, 2012; Haller, 
Duan, Benowitz, & Jacob, 2004; Roman, Hildreth, & Bannister, 2013; Thomas et al., 
2004) and UPLC (Beauchamp et al., 2016; Hasegawa et al., 2009) to quantify the 
amount of caffeine specifically in dietary supplements, caffeine powders and weight 
loss supplements and found the caffeine content in the products analysed were variable 
to that quoted on their labels. Our results are in agreeance with the trends reported in 
those studies. Note that the HPLC methods mentioned above were subject to long run 
times compared to our short run time of 10 minutes. For high throughput analyses, this 
translates to a considerable cost saving without compromising sensitivity. The 
sensitivity reported in this method confers potential applicability to supplements as well 
as biological matrices. However, further improvement of the LOD and LOQ of caffeine 
is required to improve the sensitivity of the method. To our knowledge, this is the first 
implementation of a mass-detector on a HPLC method specific to determining caffeine 
in PWS.  
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5.1 General Discussion  
 
The overall goal of this thesis was to determine the amounts of selected stimulants in 
PWS, both the biogenic amines derived from CA extracts as well as caffeine and its 
DMX derivatives. To achieve these aims, two HPLC-UV/MS protocols were 
developed. Details of the development and optimisation were discussed in Chapter 3 
and Chapter 4 for the detection of biogenic amines and the detection of caffeine and 
DMX derivatives in PWS respectively. Usability of and limitations to these methods 
are discussed later in this chapter. 
These analytical protocols were developed to answer the following research 
questions: 
1) Do CA-containing PWS comply with the 30 mg per dose limit of synephrine set 
by the TGA? 
2) Is there a discrepancy in synephrine concentrations between overseas sourced and 
locally manufactured PWS?  
3) Are the levels of caffeine measured in a range of CA-containing PWS products, 
consistent with that listed on their labels? 
Research question one was answered by determining the amounts of synephrine found 
in CA-containing PWS and comparing them to the maximum limit of 30 mg/serve 
limit set by the TGA. The concentrations of synephrine in all five PWS found were 
between 1.06 to 8.30 mg/serve. Hence, all PWS supplements tested did not exceed 
this regulated amount.  
The levels of synephrine measured in Australian-made and internationally sourced 
PWS were compared. The highest concentration of synephrine was found in a locally 
made PWS (PumpHD) (8.30 mg/serve), whereas the lowest concentration of 
synephrine was found in an internationally sourced PWS (360Rage) at 1.06 mg/serve. 
A larger sample size was needed to form a trend between the discrepancies of 
Australian and internationally made PWS.     
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Finally, the amount of caffeine and its DMX derivatives were determined and 
contrasted between local and internationally manufactured PWS. The average caffeine 
content within all PWS was quite similar despite country of origin. Interestingly, a 
locally made PWS contained traces of TP and PX. These were likely formed during 
the manufacturing process.   
The remainder of this chapter is devoted to a general discussion of the methods 
developed, their use and limitations and an interpretation of the results of the research 
in terms of relevance and future directions 
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5.1.1 Adrenergic Amines Found in CA-containing PWS 
 
Synephrine, as the main biogenic amine in CA, is classed as a Schedule 4 substance 
(prescription only medicine) in Australia with a RDD of 30 mg. PWS are considered 
complementary medicines and their importation and use is regulated by the TGA. A 
rise in popularity of this type of product for recreational use has been accompanied by 
an increase in adverse health reports and prompted warnings by regulatory bodies. 
Therefore, there was a need to investigate whether the amounts of synephrine in CA-
containing PWS meet the 30 mg RDD and if there was a discrepancy between locally 
and internationally sourced PWS.  
Once developed, the validated HPLC-UV/MS protocol was used to determine the 
levels of adrenergic amines, synephrine, tyramine and octopamine in a selection of 
PWS. These included MusclePrime (AllMax Nutrition) (A); Gold Standard 
Preworkout (OptimumNutrition) (B); 360Rage (360°Cut Performance Supplements) 
(C); ErgoBlast (ErgoGenix) (D) and PumpHD (BPISports) (E). A matrix blank (Beast 
Mode (Beast Sport’s Nutrition) was included which lacked CA and could help 
eliminate matrix-borne errors in the extraction protocol. The PWS samples A, C and 
D were purchased online (manufactured in the USA) while samples B and E were 
manufactured in Australia.  
The chromatography involved a gradient elution over a fast, 10-minute run time (A: 
water and B: acetonitrile, adjusted to pH 11 with 0.1% ammonium hydroxide) on an 
Xbridge BEH C18 column. Detection was facilitated with use of a UV/Vis-detector 
(242 nm) coupled with mass confirmation via an in-line single quadrupole (QDa) 
mass detector in positive electrospray ionisation (ESI) scan mode. This method 
proved to be successful in achieving an important feature or reduced analysis time, 
making it suitable for high-throughput analyses. Additionally, improved 
chromatography was achieved by using a less common approach to the analysis of 
adrenergic amines - the inclusion of a basic modifier at high pH. The increase mobile 
phase pH of 11 meant the use of IPRs was avoided which translates to cost saving for 
initial IPR purchase as well as eliminating the long equilibration times that 
accompany IPR use. Furthermore, since ammonium hydroxide is volatile, it is suitable 
for LC-MS, unlike IPRs. We also showed how the novel implementation of QDa 
mass detection was able enhances structure confirmation of the adrenergic amines.  
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Calibrations for each compound were linear between the range 5 µg/mL to 100 
µg/mL with determination coefficients (r
2
) greater than 0.997. The intra-day precision 
was calculated to be between the range of 2.1-4.1% for synephrine, 2.9-3.0% for 
octopamine, and 1.4 to 5.3% for tyramine. According to the FDA guidelines for 
pharmaceutical determination, RSD% values of less than 15% were considered 
satisfactory (FDA, 2013). The accuracy was determined by adding a known amount 
of standard to a blank matrix according to the ICH standards guidelines. In this 
analysis, the accuracy of all the amines was between 77-105%. A majority of the 
accuracy values were acceptable In the case of octopamine and tyramine there was a 
trend for lower accuracy at the LOD (5 µg) as well as the higher range of 100 µg/mL 
(80%).  This could possibly be due to loss during sample preparation or simply 
experimental error in technique. This former could be improved by using a higher 
concentration of non-polar solvent (ACN) during the sample preparation to aid in the 
retention of the compounds during the SPE process.  
Table 23 summarises the amount (reported as mg/g) of synephrine, octopamine and 
tyramine found in our tested PWS and compared against the concentrations obtained 
in a standard reference material (SRM 3258) by Putzbach et al. (Putzbach et al., 
2007).  
Table 23 Synephrine, octopamine and tyramine content in PWS and SRM 3258(mg/g) 
Compounds of 
interest 
Concentration of amines found in samples (mg/g) 
 (mean ±RSD %) Yield 
from 
SPE 
(%) 
 
Amount 
of 
amines 
found in 
SRM 
3258 
(mg/g) 
A B C D E 
Synephrine 
0.25 ± 
9.3 
0.31 ± 
5.6 
0.15 ± 
2.9 
0.70 ± 
1.5 
0.89 ± 
1.8 
98.0± 
1.2 
8.65 
       
Octopamine 
0.10 ± 
10.2 
4.46 ± 
12.7 
0.28 ± 
4.6 
8.90 ± 
10.1 
0.65 ± 
3.8 
110.3 ± 
6.3 
0.14 
       
Tyramine 
0.10 ± 
2.5 
0.52 ± 
0.4 
0.28 ± 
1.1 
0.28 ± 
2.0 
0.69 ± 
3.9 
96.7 ± 
0.6 
0.026 
*PWS highlighted in red were Australian-made products 
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The concentrations of biogenic amines in certified standard reference materials were 
presented in mg/g of a standardized source of a CA fruit. The ratios of the biogenic 
amine within the standard were approximately 10: 01: 0.02 (mg/g) for synephrine: 
octopamine: tyramine (Putzbach et al., 2007). Thevis et.al measure a similar ratio of 
biogenic amines in a single CA extract where the ratios were 5: 0.09: 0.03 (mg/g) 
(Thevis et al., 2012). We reported our findings in mg/g of supplement where the exact 
quantities of CA extract added were unknown. When contrasted to our findings, it 
was evident that the ratios of biogenic amines found were significantly higher for 
octopamine and tyramine, but lower for synephrine. 
To compare concentrations of actives between PWS samples, we calculated according 
to their serving size (Table 24) 
Table 24 Amount of amines found calculated to the serving size of the PWS (mg/serve) 
  
Samples 
Amount of amines found in PWS (mg/serve) (mean ± RSD %) 
Synephrine Octopamine Tyramine 
A (MusclePrime) 
 
4.69 ± 9.3 1.97 ± 10.2 1.95 ± 2.5 
B (Gold Standard 
Preworkout) 
 
3.11 ± 5.6 44.62 ± 12.7 5.17 ± 0.4 
C (360Rage) 
 
1.06 ± 2.9 2.03 ± 4.6 2.05 ± 1.1 
D (ErgoBlast) 
 
3.49 ± 1.5 44.52 ± 10.1 1.39 ± 2.0 
E (PumpHD) 
 
8.30 ± 1.8 6.54 ± 3.8 6.90 ± 3.9 
*PWS highlighted in red were Australian-made products 
Levels of p-synephrine were in line with other reported methods of between 0.001 
mg/g to 8.65 mg/g (Avula, Upparapalli, Navarrete, et al., 2005; Ganzera et al., 2005; 
Marchei et al., 2006; Pellati & Benvenuti, 2007; Pellati et al., 2002; Roman et al., 
2007; Slezak et al., 2007).  PumpHD, an Australian-made PWS, had the highest levels 
of synephrine (8.3mg/ serve), whereas the lowest level of synephrine (1.06mg/ serve) 
was found in 360Rage, an internationally manufactured PWS. A much larger sample 
size would be required for testing before any trend or conclusion could be made in 
relation to comparing Australian to overseas-made PWS. There would also be scope 
to test locally sourced and internationally sourced variants of the same brand to 
observe the discrepancies between them. After recalculating the amounts found in our 
analysis to its respective serving size, it was observed that all synephrine found did 
not exceed the TGA’s RDD of 30 mg/serve.  
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Octopamine was detected in high concentrations (44 mg/serve) in one locally-made 
PWS (Gold standard Preworkout) and one made overseas-made PWS (ErgoBlast). 
Octopamine was found in CA extracts in amounts between 0.12 mg/g to 0.8 mg/g 
(Sander et al., 2008). The high level of octopamine determined was not in line with 
the apparent ratio of the biogenic amines found in the SRM and thus in these PWS 
suggests it may have been added rather than simply being present as a component of 
CA. Currently, there no legal limits or RDDs for octopamine use in dietary 
supplements in Australia although, due to its stimulatory properties, it is a banned 
substance in athletic competitions (World Anti-doping Agency, 2015). WADA has 
not stated a specific acceptable level of octopamine above which penalties apply. 
With further improvements to sensitivity for detection biological matrices, this 
method could find use in the quantification of octopamine in the anti-doping arena.  
Tyramine, while not listed on any PWS labels was detected in all samples tested. The 
highest level of tyramine quantified was 0.69 mg/g in a locally made PWS. However, 
when calculated to its serving size, the concentration of tyramine is 6.9 mg/serve, 
higher than some synephrine found in the other PWS. Tyramine has been attributed to 
microbial decarboxylases on amino acids such as tyrosine during handling and 
packaging or during the preparation of these PWS (Farah, 2012). PumpHD 
specifically uses Theobroma cacao seed extract, which is prepared by roasting 
Theobroma cacao seeds. This process could release and increase the amount of amino 
acid decarboxylation, attributing to the higher amount of tyramine. Like octopamine, 
there are no current restrictions on the maximum limits for tyramine in supplements. 
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5.1.2 Caffeine and DMX Found in PWS  
 
In Australia, manufacturer are required to list caffeine on  product labels however 
there are no set maximum limits for PWS. For food additives however, the FSANZ 
has set the RDD for caffeine to 210 mg/day (approximately 3 cups of coffee/day). For 
the accurate quantification of total stimulants in PWS, one must include caffeine and 
its DMX derivatives in the analysis. In addition, since some products do provide 
actual levels of caffeine on their labels, comparisons were made the measured levels.  
To address the third research question a rapid HPLC-UV/MS protocol was developed 
and validated for the quantification of caffeine and DMX in locally and overseas 
made PWS.  
The chromatography involved a gradient elution over a fast, 10-minute run time (A: 
water and B: acetonitrile, adjusted to pH 4.5 with 0.1% formic acid) on a CSH 
phenyl-hexyl column, detected with a UV/Vis-detector (272 nm) coupled with mass 
confirmation on a QDa mass detector in positive ESI mode. Repeatability, according 
to the AOAC should not exceed 1.25% RSD ((AOAC), 2012), our  repeatability 
values were considered satisfactory for the retention times as indicated by %RSD 
range of 0.06 – 1.14% These results are in line with the standards set out by ICH for  
acceptable single-laboratory assay precision. However, additional validation by 
incorporating ‘between laboratories’ testing would strengthen the overall validation of 
this method.  
The quantitative recoveries ranged from 81.8 – 89.2%, with %RSD 0.5 – 2.57% 
which is satisfactory according to the ICH guidelines. However, yield improvements 
are indicated given noticeable losses during the sample preparation. This could be 
improved by using a higher concentration of non-polar solvent (ACN) during the 
sample preparation. 
 
 
 
 
   
120 
Table 25 shows the content of caffeine and DMX (mg/g) in the sample PWS. How 
these four compounds are introduced into the PWS depends on whether they’re part 
of a plant extract or a separate additive. For example, if from plant origin, then PX 
should not be expected to be present. Interestingly PX was found in one locally-made 
PWS (PumpHD) albeit at low levels. While a complete understanding of the 
physiological effects of PX are not well researched reports of increased skeletal 
muscle contractility have been described (Hawke et al., 2000; Orru et al., 2013). An 
additional source of TP and PX could be attributed by the actions of filamentous 
fungi. Hakil et.al observed the demethylation of caffeine to TP via the Aspergillus and 
Penicillium genus strains of fungi (Hakil et al., 1998). PumpHD contains Theobroma 
cacao extracts likely to be the source of caffeine. Potential degradation of caffeine to 
these DMX compounds could occur during the storing or processing phase of product 
manufacturing.   
Table 25 Caffeine and methylxanthine content in PWS (mean +/- SD) (mg/g PWS) 
Products 
Caffeine 
(mg/g)  
Theobromine 
(mg/g) 
Theophylline 
(mg/g) 
Paraxanthine 
(mg/g) 
A 
20.10  ± 
1.81 
1.12 ± 0.15 N/A N/A 
B 
15.70  ± 
1.53 
N/A N/A N/A 
C 
25.30  ± 
1.21 
N/A 0.31± 0.02 0.03 ± 0.01 
D 
9.89  ± 
0.39 
2.57 ± 5.77 N/A N/A 
E 
24.00 ± 
0.16 
3.03 ± 0.10 N/A N/A 
*PWS highlighted in red were Australian-made products 
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Comparison of measured caffeine to labelled quantities if present was made by 
adjusting to serving size (Table 26). 
Table 26 Amount of caffeine present compared to its PWS label 
Products 
Amount of 
Caffeine 
Quantified 
(mg/mL) 
Caffeine listed on 
the label (mg) (per 
serving size) 
Actual 
amount of 
caffeine* 
(mg)(per 
serving size) 
A 
(KardioFire) 
 
20.10 ± 1.81 Not listed 
201.44 ± 
18.1 
B 
 (360Rage) 
 
15.70 ± 1.53 Proprietary Blend 
156.96 ± 
15.3 
C 
 (PumpHD) 
 
25.30 ± 1.21 Proprietary Blend 
189.60 ± 
9.06 
D 
(MusclePrime) 
 
9.89± 0.39 100 
187.89 ± 
7.14 
E 
 (DyNO) 
 
24.00 ± 0.16 300 
179.86 ± 
1.20 
*Average 181.15 ±9.03 RSD % 
**PWS highlighted in red were Australian-made products 
Interestingly, despite the country of manufacture of the PWS, the average caffeine 
content was quite similar with a relatively low RSD%. Noticeably however the 
amount per serving size is just under the RDD of a maximum of 210 mg per day 
mentioned above.  The implication for consumers is that it is likely, with so many 
other sources of caffeine in the modern diet that over consumption may regularly 
occur. In addition, two or more servings of the PWS per day can easily raise caffeine 
consumption into dangerously high levels.   
In some instances, there are discrepancies between measured product content from 
that stated on product labels. This finding is consistent with other studies which found 
similar differences (Beauchamp et al., 2016; Gurley et al., 2004).  
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The protocol successfully separated TP and PX. As explained earlier, TP and PX are 
isobaric isomers that differ in the position of a methyl group (as with TB). The 
difficulty this presents to the analyst is reflected in the paucity of studies which show 
their clear resolution. Researchers often explain this omission by the absence of PX in 
food and plants. The use of the QDa mass detector aided in the confirmation of these 
isomers during quantitation in PWS supplements however this was only possible once 
peak resolution has been achieved. Since PX was detected in one of the supplement 
(C), it is clear that attention should be given to this analyte regardless of its origin. 
Otherwise levels of TP could be overestimated. It is possible that PX has been 
specifically added in order to increase the overall stimulatory effect of caffeine in 
PWS. Further testing in a higher sample number is required to confirm whether this 
was a ‘one-off’ finding in PWS formulations or a more common practice. 
Apart from its reliability and fast run time, this method has the potential for 
applicability to both commercial products and biological fluids since it completely 
resolves the isobaric compounds, TP and PX. However, further improvements and 
validations are required by conducting validations on a larger sample size. Since the 
typical caffeine content in urine is in the range 2 µg/mL to 15 µg/mL, there is scope 
for this method to be transferrable to the analysis of caffeine and its metabolites in 
biological fluids This would be of benefit to sporting regulatory bodies, such as 
Australian sport anti-doping agency (ASADA) or WADA, where screening is 
conducted for particularly for caffeine levels above 12 µg/mL. However, by only 
measuring caffeine in the urine and not its metabolites, underestimation of caffeine 
content originally consumed is likely.  
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5.2 Limitations  
 
A number of limitations should be mentioned. First and foremost, the number of PWS 
selected was too small for any trends or conclusions to be drawn with respect to 
comparing locally made to overseas manufactured products. A much larger sample 
size would be required to draw such conclusions. Notwithstanding the above, the 
results obtained from this pilot data could be used to justify further work extending 
the scope for a much larger sample set. In addition, the batch of supplements were 
sourced in 2015 but had not surpassed their expiry date. There was still potential for 
component degradation could result in an under determination of the analytes as the 
nature of handling and storage of PWS prior to purchase was unknown.  
An improvement for the quantification of caffeine and DMX could have been in the 
way in which the IS (etofylline) was used. In this protocol only, the IS was used for 
analyte recovery determination during sample preparation rather than the normal 
function in calibration to account for variability due to analyte losses in storage or 
treatment for example.  
The QDa mass detector was able to scan the masses of compounds ranging from 
100Da to 1300Da. The benefits of linking the LC system to the QDa detector were the 
enhanced ability to confirm structure identity. While single-quadruple magnet systems 
such as this are unable to reach anywhere near the degree of accurate mass detection 
or range of structure detection possible with more complex, tandem MS systems, they 
can be a powerful tool when used as a mass detection tool. Fragmentations can be 
tracked with a confidence level of ±0.1 Da. This is not satisfactory for many analyses. 
However their comparative cheaper cost makes them an attractive option depending 
on the requirements for use.  
Additional experimental errors may have occurred during the sample preparation 
phase. It was evident that the analytical recoveries after the SPE were especially low 
at lower concentrations. This indicates a problem with small volume delivery. This 
could be improvements to technique, adjusting to larger volumes or by further 
validating the SPE method protocol by optimising the organic elution phase. The use 
of a centrifugation and extraction method could have been beneficial to the 
determination of stimulants due to the complex matrix of the PWS. 
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5.3 Future Directions for the Analysis of Stimulants in PWS  
 
To improve the sensitivity of the amphetamine-like compound protocol, Hydrophilic 
Interaction Chromatography (HILIC) could be used. HILIC has been used in the 
analysis of small polar compounds such as pharmaceutical, toxins, plant extracts and 
other compounds important to food and pharmaceutical industries. (Jandera, 2011; 
Karatapanis, Fiamegos, & Stalikas, 2011; McCalley & Neue, 2008).   
A small number of studies have used HILIC as a means of separation for ephedrine and 
synephrine. A first study by Heathon, investigated the suitability of bare silica HILIC as 
an alternative to conventional RP-HPLC for the fast chromatographic separation of 
ephedrine isomers. The study reported the effects of chromatographic parameters 
including the proportion of acetonitrile, buffer, pH and the column temperature in 
HILIC separation (Heaton et al., 2012). Faster retention times and symmetrical peaks 
were achieved on the HILIC method over HPLC conditions coupled with the advantage 
of MS compatibility.   
This was followed by a more comprehensive study by Jovanovic et al who investigated 
parameters such as mobile phase and other process parameters on HILIC separation of 
ephedrine and synephrine (Jovanović, Rakić, Ivanović, & Jančić–Stojanović, 2015). 
The method successfully separated the diasteroisomers, ephedrine and pseudoephedrine 
as well as the positional isomers of synephrine and phenylephrine.  However, the linear 
calibration was not reported and the correlation coefficients were r
2
= 0.990 could be 
improved by optimising the range of standards used. Sakai et al used a zwitterionic 
monolith column paired to an electrochemical detection system. The authors 
demonstrated the use of electron capture dissociation (ECD) in HILIC with a LOD of 
3.7 pg (Sakai et al., 2016). Future work implementing a HILIC column, for the analysis 
of the adrenergic amines within CA should be undertaken and compared to the current 
method to improve the sensitivity in detecting these compounds in PWS or biological 
matrices. 
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Further analytical studies could be undertaken to detect other synthetic stimulants, not 
of plant origin but reported to be present in recently released PWS. These reports 
describe banned supplements containing novel synthetic stimulants – many of which 
lack appropriate evidence for safety in humans (Archer et al., 2015; Cohen, 2012; 
Venhuis et al., 2014). Synthetic stimulants such as DMAA, amphetamine and 
methamphetamine analogues have often been sold as a compound within herbal 
extracts. DMAA ( C7H17N) is an aliphatic amine with a pharmacophoric structure 
similar to amphetamine (Figure 40). Its sympathomimetic mechanism of action is 
similar to amphetamine. A study conducted in 2013, was the first to characterise the 
oral pharmacokinetic profile of DMAA, where it was found that DMAA did not impact 
heart rate, blood pressure or body temperature (Schilling, Hammond, Bloomer, Presley, 
& Yates, 2013). However, this short-term study only involved eight healthy men 
providing blood samples collected over a 24 hour period. One subject was excluded due 
to reported abnormal DMAA levels.  
     
1,3-Dimethylamylamine (DMAA)    Amphetamine 
Figure 40 Structural simiarities between DMAA and amphetamine 
 
A challenge with detecting DMAA and its analogues by the common technique of UV 
spectrophotometry is their lack of a chromophore. In addition, their presence in PWS is 
often masked by claims that they are constituents of natural plant extracts and so are not 
listed individually. For example,  DMAA has been labelled as present in geranium oil 
(Zhang, Woods, Breitbach, & Armstrong, 2012), methamphetamine analogue, N, α-
diethylphenylethylamine (DEPEA) labelled as dendrobium orchid (Cohen, Travis, & 
Venhuis, 2014) and 1,3-dimethylbutylamine (DMBA) was marketed as an extract of 
Pouchung tea (Cohen, Travis, & Venhuis, 2015). 
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Finally, receptor binding studies for these adrenergic amines are quite limited, which 
limits a more complete understanding of their pharmacology. As mentioned in chapter 
1, synephrine has been described to be an α-AR agonist (Carpene et al., 1999). 
However, the specific subtypes of α-adrenoceptor binding have yet to be explored. This 
presents a clear gap in knowledge and an opportunity for the investigation into the 
receptor binding properties of these amines using either cell-based and or tissue-based 
experiments. Computational approaches such as molecular docking and dynamics could 
search for unique features of the receptor subtypes which may help explain any 
observed differences in binding and/or function. Molecular dynamic simulations could 
be used to computationally derive the binding affinities and compared to the known 
proposed (α1-, α1-, β2-, β3-) adrenergic and trace amine-associated receptor 1 (TAAR-
1).    
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5.4 Concluding Remarks 
 
The aims and research questions have been addressed by the development of two rapid, 
accurate and validated HPLC protocols for the quantitation of 1) adrenergic amines 
present in CA-containing PWS and 2) caffeine and DMX present in PWS. To the best 
of my knowledge, these methods were the first to implement a QDa detector for rapid 
mass detection in-line with UV detection on a RP-HPLC system for quantification of 
these compounds. Levels of synephrine in both locally and overseas- made PWS were 
compliant with the TGA’s regulation of a limit of 30 mg/serve. A greater sample size of 
CA-containing PWS is likely required to determine any real differences in synephrine 
levels between locally and overseas-made PWS. 
It was hypothesised that the amounts of caffeine found in overseas made PWS would be 
higher than locally sourced PWS. This was not the case however, significant variability 
was observed in the levels of caffeine found in both locally and overseas made PWS 
when compared to the stated quantity on its label. A further highlight of this study was 
the development of a method with the ability to resolve the isobaric isomers, TP and 
PX. PX was also found in one of the overseas supplement albeit in small amounts.  It 
was noted that when the compounds were present as a ‘proprietary blend’ this poses an 
obstacle to accurately compare the quantities of the key ingredients with their labels.  
Future research into the quantification of these amines and other synthetic stimulants on 
a HILIC could result in greater sensitivity of the methods especially when coupled to a 
mass detector. 
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Appendices 
 
Appendix 1: Muscle Prime (Allmax Nutrition) label 
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Appendix 2 Gold standard Preworkout (Optimum Nutrition) label 
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Appendix 3: 360Rage (360°Cut Performance Nutrition) label 
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Appendix 4: ErgoBlast (Ergo Genix) label 
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Appendix 5: PumpHD (BPI Sports) label 
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Appendix 6: BeastMode (Beast Sports Nutrition) label 
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Appendix 7: KardioFire  (Panthera Pharma) label 
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Appendix 8: DyNO (RSP Nutrition) label 
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Appendix 9: Scheduling 1-10 that is currently implemented by the Therapeutic 
Goods Administration of Australia 
 
Schedule 1 This Schedule is intentionally blank. 
Schedule 2 
Pharmacy Medicine – Substances, the safe use of which may require advice from a pharmacist 
and which should be available from a pharmacy or, where a pharmacy service is not available, 
from a licensed person. 
Schedule 3 
Pharmacist Only Medicine – Substances, the safe use of which requires professional advice but 
which should be available to the public from a pharmacist without a prescription. 
Schedule 4 
Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply 
of which should be by or on the order of persons permitted by State or Territory legislation to 
prescribe and should be available from a pharmacist on prescription 
Schedule 5 
Caution – Substances with a low potential for causing harm, the extent of which can be reduced 
through the use of appropriate packaging with simple warnings and safety directions on the 
label. 
Schedule 6 
Poison – Substances with a moderate potential for causing harm, the extent of which can be 
reduced through the use of distinctive packaging with strong warnings and safety directions on 
the label. 
Schedule 7 
Dangerous Poison – Substances with a high potential for causing harm at low exposure and 
which require special precautions during manufacture, handling or use. These poisons should be 
available only to specialised or authorised users who have the skills necessary to handle them 
safely. Special regulations restricting their availability, possession, storage or use may apply 
Schedule 8 
Controlled Drug – Substances which should be available for use but require restriction of 
manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical or 
psychological dependence. 
Schedule 9 
Prohibited Substance – Substances which may be abused or misused, the manufacture, 
possession, sale or use of which should be prohibited by law except when required for medical 
or scientific research, or for analytical, teaching or training purposes with approval of 
Commonwealth and/or State or Territory Health Authorities 
Schedule 
10 
Substances of such danger to health as to warrant prohibition of sale, supply and use - 
Substances which are prohibited for the purpose or purposes listed for each poison. 
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Appendix 10 : Calibration curve of synephrine from concentrations 2 µg/mL to 
200 µg/mL. r
2 
= 0.9129 
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Appendix 11 : Calibration curve of octopamine from concentrations 2 µg/mL to 
200 µg/mL. r
2 
= 0.9061 
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Appendix 12 : Calibration curve of tyramine from concentrations 2 µg/mL to 200 
µg/mL. r
2 
= 0.87217 
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